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Abstract 
Title: Creating recombinant fusion protein conjugates for targeting SNARE protease 
into neuroendocrine cells 
 
Author: Nilesh Baliram Patil 
Chronic pain poses major healthcare and economic burdens.  The aim of this study was to 
develop a strategy for pain management by generating a biotherapeutic that requires 
targeting of soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein 
receptor (SNARE) within the hyper-active sensory nerves. This entailed conjugating nerve 
growth factor (NGF) and the SNARE-cleaving protease and internalization domains of 
botulinum neurotoxin A (BoNT/A). The methodology involved genetic fusion and use of a 
protein stapling technology with a view to replacing the BoNT/A C-terminal neuronal 
binding subdomain (HCC) with βNGF which is a specific ligand for preferential sensory 
neuronal targeting. A first generation of BoNT/AΔHCC fused to βNGF was expressed in E. 
coli and purified.  An alternative strategy was also adopted with a view to stapling a 
recombinant BoNT/AΔHCC-SNAP-25 protein (without the neuronal binding domain) with 
Vamp2.βNGF produced in E. coli, and a synthetic syntaxin-1 peptide via SNARE complex 
formation. Treatment of PC-12 cells with BoNT/AΔHCC fused to βNGF did not give any 
cleavage of intracellular SNAP-25. Failure to redirect BoNT/A protease into PC-12 cells 
was attributed to inactivity of the βNGF producing E. coli. After a number of attempts, the 
precursor peptide (Pre-Pro signal peptide) of NGF was identified as an essential element in 
making a biologically-active βNGF. Encouragingly, after inclusion of this leader peptide 
sequence into a Vamp2.βNGF construct, it was expressed as an active protein, although 
with low yield. The latter was addressed by creating a construct encoding a Pre-Pro signal 
peptide followed by βNGF.Vamp2 in the hope of increasing the yield. Expression of the 
 xx 
   
resultant protein was not attempted. In summary, expression of functionally-active 
βNGF.Vamp2 was achieved. Further optimization is needed before its conjugation to the 
BoNT core-therapeutic domains, for redirecting SNARE-cleaving protease into hyper-
active sensory nerves. 
  Chapter 1  
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Preamble 
A European consensus report by Pfizer (Chronic pain management 2010) revealed that the 
total costs to the Irish GDP arising from chronic pain were estimated at €5.34bn per year. 
The same report asserted that one in three people in Ireland who have chronic pain are 
struggling with their condition and fear that their illness and absences from work may 
mean loss of their jobs. Effective means to manage chronic pain are urgently needed to 
both improve the quality of life of sufferers and reduce health care costs (Katz et al. 2010, 
Lippe et al. 2010). This is borne out by a survey on chronic pain within 16 European 
countries conducted by Breivik et al. 2006, which stated that chronic pain occurred in 19% 
of 46394 respondents, two thirds of which were moderately affected and one third were 
severe cases, having a negative impact on their daily activities, social and working lives. 
Another study carried out by Rafferty et al. 2011 in the Republic of Ireland reported that 
chronic pain was prevalent within 35.5% of the 1204 respondents. Their study reported that 
12% of respondents were unemployed or were working on reduced working hours due to 
chronic pain. Blyth et al. 2003 highlighted the effects of chronic pain on the ability to work 
and the consequent implications for the economy. This report included factors such as, the 
cost related to the loss of productivity due to time off work, reduced work effectiveness 
and the cost in loss of skills in cases where people reduced their working hours or stopped 
working altogether.  
The International association for the study of pain (IASP) published on their website a 
meta-analysis on prevalence of chronic pain based on 13 worldwide studies. The data 
reported in these studies indicate a higher prevalence of chronic pain suffers among 
females and significant use of health care resources by chronic pain sufferers. The 
prevalence figures show that the costs associated with severe chronic pain are significant 
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for health systems in the countries surveyed (International association for study of pain 
2003). 
 Neurobiology of pain 1.1
IASP defines pain as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of such damage (Bonica 1979; 
National institute of Health 2014). The word pain is derived from the Greek word meaning 
‘penalty’. 
1.1.1  Nociceptors 
Receptors on the peripheral ending of different nerves respond to a variety of stimuli. Their 
shape, location and field of reception indicate that they are designed for response to their 
stimuli. The pain receptors (nociceptors) have primitively-organized nerve endings and a 
weed-like appearance. The strength of the stimulus is a critical factor in the production of 
pain. When a certain threshold of intensity has been surpassed, any stimulus can be 
interpreted as painful to nociceptors. This threshold stimulus is called the noxious stimulus 
and it causes tissue damage (Hall 2002; Julius and Basbaum 2001). 
1.1.2 Afferent fibers 
An afferent nerve fiber is the nerve fiber (axon) of an afferent neuron (sensory neuron). 
First order afferent nerve fibers are classified according to their size and conduction rates 
(Fig.1). A-fibers are the largest in diameter and most rapid in conduction rates. B-fibers are 
intermediate in size and have a slow conduction rate. C-fibers are smallest in size and 
slowest conduction rate.  
  Chapter 1  
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There are two types of primary afferent nociceptors, Aδ and C fibers. Aδ is one of four 
types of A-fibers (Aα, Aβ, Aγ, Aδ). Aδs are the most rapid pain conducting fibers 
compared to C conducting fibers. Pain signals conducted  by Aδ fibers are described as 
sharp, shooting and intense,  with a velocity of ~6-25 m/s. Aδ fibers are lightly myelinated, 
medium diameter size (1-5 μm) and have free nerve endings that transduce high threshold 
thermal, mechanical and chemical noxious stimuli. Aδ fibers make up 20% of pain 
afferents and mediate pain from superficial areas such as skin. C fibers are the slowest pain 
conducting. The pain conducted by C fibers is described as steady slow (<2 m/s) and 
constant. C fibers are unmyelinated and their diameters are small in size. C fibers account 
for 80 % afferent pain fibers and arise from non-localized polymodal nociceptors i.e. 
nociceptors that respond to wide range of noxious stimuli. Cell bodies of C fibers are 
located in dorsal root (spinal cord) or trigeminal ganglia (brain) of spinal cord and their 
axons terminate in the dorsal horn Hall James 2002; Julius and Basbaum 2001). 
 
   
A B 
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Fig.1 Classification of nociceptors.  A) Peripheral nerves consist of myelinated afferent fibers 
Aδ (medium-diameter), Aα, β (large-diameter) and unmyelinated afferent C fibers (small diameter). 
B) Schematic of peripheral nerve action potential. Aδ and C fibers differ in their conduction velocity 
(6-25 and ~1 m/s, respectively) and represent their first and second responses to painful stimuli. 
Image taken from Julius and Basbaum, 2001. 
1.1.3 The spinal cord and transmission of signal 
The role of the spinal cord in the transmission mechanism of pain is important because 
information processing occurs in the dorsal horn grey matter. The spinal cord consists of 
two symmetrical halves, the dorsal median sulcus and the ventral median fissure separated 
with a small central canal in the center. The canal is surrounded by grey matter composed 
of nerve cell bodies, dendrites and synaptic connections. The outer region of the spinal 
cord contains white matter comprising of ascending and descending nerve fibers. The grey 
matter forms an H butterfly shape and the dorsal horn forms an arrangement of six layers 
(numbered in Fig. 2) as per their Rexed classification system (identified in the early 1950s 
by Bror Rexed to label portions of the grey columns of the spinal cord). Acute nociceptive 
pain, stimulates the release of pain mediators from primary afferent terminals that project 
to laminae I, IV and V in the spinal cord dorsal horn. Having been relayed to the lateral 
spinothalmic tract, pain signals from Aδ fibers travel to the ventrobasal to posterior nuclei 
or to the thalmic relay nuclei and after that to the post central somatosensory area of the 
cerebral cortex. Similarly, signals sent by the C fibers having reached the medial nucleus of 
the thalamus, continue to the prefrontal somatosensory region of the cerebral cortex 
(Rudolf et al 2007). 
  Chapter 1  
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Fig. 2 Spinal cord and transmission of pain signals.  Pain receptors transmit pain signals 
to the dorsal horn of spinal cord. Primary afferent terminals that project to dorsal horn laminae I, IV 
and V, release pain mediators upon acute pain stimulation. Aβ, Aδ and C fibers also project to 
laminae II–VI. Dorsal root ganglia (DRG) propagate pain signal to dorsal spinal cord, brain stem 
and eventually to the brain where pain is perceived. Image taken from Milligan and Watkins, 2009. 
1.1.4 Classification of pain 
Pain is an unpleasant subjective sensory experience induced by noxious stimuli, 
inflammation or damage to the nervous system which can be classified according to its 
type (Fig. 3). Nociceptive pain is the most widely experienced short-acting sensation to a 
noxious stimulus. It acts as an essential alarm system to alert the nociceptors i.e. sensory 
receptors in the peripheral nervous system, which are activated by painful stimuli. These 
pain signals are propagated from the periphery through the spinal cord, brain stem, and 
thalamus to the cerebral cortex, where the sensation is perceived. Nociceptive pain is an 
 
Laminae 
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important and essential alarm system that alerts the individual of fore coming danger to 
prevent the body from damage. Those that have inefficient nociceptive control systems, 
including patients with congenital analgesia (resulting from a nerve growth factor tyrosine 
kinase A mutation that leads to a loss of high-threshold sensory neurons), have reduced life 
expectancies due to their inability to protect themselves from harmful noxious stimuli 
(Miranda et al.,2002).  
Acute, inflammatory pain is produced by tissue damage resulting in the release of 
peripheral inflammatory mediators to the affected inflamed area.  The purpose of this 
short-term response is to encourage healing. Following inflammation, the sensory nervous 
system adapts by lowering the nociceptor activation threshold, so that normally non-painful 
stimuli produce pain (allodynia) and responses to noxious stimuli are enhanced 
(hyperalgesia).  Once the site of injury heals, this pain usually subsides; however, in some 
cases it may become chronic.  
Where there are lesions to the peripheral or central nervous systems, neuropathic pain 
results because of alterations in plasticity and the lowering of nociceptive thresholds, 
which in turn produce allodynia, hyperalgesia and secondary hyperalgesia (transfer of 
sensitivity to the non-injured area). (Woolf, 2004; Miranda et al. 2002).  
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Fig. 3 Classification of pain. Pain can be divided according to its types (nociceptive, 
inflammatory, and neuropathic).  Nociceptive pain is produced in response to noxious stimuli, while 
inflammatory pain arises from tissue damage. Neuropathic pain is caused by lesion to the 
peripheral or central nervous systems. Image taken from Woolf, 2004.   
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 Chronic pain 1.2
Long-term inflammatory, neuropathic and functional pain is described as chronic pain 
which can arise in a range of conditions as for example arthritis, multiple sclerosis, chronic 
shoulder and back pain, chronic migraine and myofascial pain. 
1.2.1 Peripheral sensitization and central sensitization 
The presence of repeated stimuli in chronic pain situations reduces the threshold of 
nociceptive afferents and enhances the responsiveness of the peripheral terminals of 
nociceptors, resulting in what is termed as peripheral sensitization. This peripheral 
sensitization, resulting in normally innocuous insults being perceived as noxious, is 
induced by the action of neuropeptides and inflammatory mediators released by either Ca
+2
 
regulated exocytosis such as substance P, CGRP, bradykinin, nerve growth factor, 
serotonin or neuropeptide Y or by non-exocytosis mechanisms (e.g. nitric oxide, 
prostaglandins or H
+
) (Dray, 1995). Released neuropeptides and inflammatory mediators 
amplify the conduction of nociceptive impulses and, thereby, transfer to the cell bodies in 
the dorsal root or trigeminal ganglia, producing central sensitization (Latremoliere and 
Woolf, 2009; Woolf, 2011). Both sensitizations contribute enormously to inappropriate 
hyper-responsiveness to signaling substances. 
1.2.2 Elevated levels of βNGF in chronic pain 
NGF was discovered more than half a century ago as a protein involved in a variety of 
processes including cell signaling, cell differentiation, cell survival, and cell death within 
the peripheral nervous system (Wiesmann et al. 1999; McKelvey et al. 2013). There is 
growing evidence that NGF contributes to a variety of chronic states. McKelvey et al. 
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(2013) asserts that NGF plays an important role in mediating chronic pain, based on their 
findings that levels of NGF are abnormally elevated in a number of health conditions 
including rheumatoid arthritis, spondyloarthritis (Aloe et al. 1992; Halliday et al. 1998; 
Barthel et al. 2009), neurogenic overactive bladder, interstitial cystitis (Lowe et al. 1997; 
Oddiah et al. 1998; Jacobs et al. 2010; Liu et al. 2010) and cancer-induced pain (Manthy et 
al. 2010; Ye et al. 2011). In regard to the latter, Bradshaw et al. (2015) suggest that NGF 
and Pro-NGF (a precursor form of NGF) regulate breast cancer cell survival and enhance 
cell invasion, respectively. They suggested that prostate cancer cells over-express ProNGF 
whereby they induce neuritogenesis which increases cancer progression. The mechanism 
for this process remains unclear. Genetic mutations in the NGF and TrkA genes result in 
rare and severe condition of congenital insensitivity (loss of pain perception) (Indo et al. 
1996; Einarsdottir et al. 2004; Carvalho et al. 2011; McKelvey et al. 2013). Genetic 
mutations in NGF or its receptor TrkA can cause the inability in humans to perceive pain 
(Rotthier et al. 2012 and McKelvey et al. 2013). These conditions come under the broader 
category of hereditary sensory autonomic neuropathies (HSANs) (Rotthier et al. 2012). 
Five types of HSAN’s have been suggested (McKelvey et al. 2013; Rotthier et al. 2012), 
where in each condition the affected person loses the ability to perceive pain. HSAN IV 
and HSAN V are caused by mutations in TrkA and NGF, respectively (McKelvey et al. 
2013).  
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1.2.3 Mechanisms of NGF in pain mediation 
A subset of sensory neurons express TrkA (Fang et al. 2005; Franklin et al. 2009) and 
TRPV1 (a non-selective ligand-gated cation channel). In nociceptive neurons, transmission 
of the pain signal results when an external or internal source such as thermal, mechanical 
or chemical (acids and lipids) stimulate the influx of Ca
2+
 via the opening of a channel e.g. 
TRPV1 (Moran et al. 2004; Ramsey et al. 2006). Lewin et al. (2014) provided a detailed 
description of how NGF regulates pain in nociceptive neurons via the action on mast cells 
(Fig 4). Following injury or inflammation, innate immune response mechanisms involving 
the action of mast cells, interleukins (IL -1, IL3), cytokines etc. are activated in the affected 
area. While the mechanism is unclear, it has been hypothesized (Lewin et al. 2014) that 
these cells cause an increase in NGF expression. NGF decreases the threshold for action 
potential generation through (1) producing an internalized NGF-TrkA complex that 
activates phospholipase C in sensory neurons. Breakdown of phosphotidyl inositol 
phosphates (PiPs) by the latter causes a decrease in threshold at which the transient 
receptor potential vanilloid type I (TRPV1) (which binds PiPs) channel opens (also known 
as TRPV1 sensitization) (Chuang et al. 2001), and (2) NGF induces an upregulation of 
TRPV1 expression and its trafficking to the plasma membrane (Stein et al. 2006 and Ji et 
al. 2002; McKelvey et al. 2013). Kawamoto et al. (2002) suggests that NGF plays a crucial 
role in sensitizing the adjacent nociceptive neurons of the PNS. They stated that NGF 
facilitates the release of both other pain mediators such as histamines and prostaglandin 
and causes release of NGF from mast cells, leading to the formation of a positive feed-back 
loop in the transmission of pain signal. Hefti et al. (2006) and Mantyh et al. (2011) stated 
that NGF additionally plays an important part in sensitizing nociceptive neurons in the 
CNS via the upregulation of genes encoding substance-P, sodium ion channels such as 
Nav1.8, brain-derived neurotrophic factor; this central role of NGF signaling in pain is not 
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relevant to this study described here and will not be discussed further. Rather I will focus 
on the peripheral role of NGF signaling in pain. 
 
 
 
 
 
 
 
 
 
Fig. 4 Mechanisms through which NGF facilitates pain transmission. An increase in 
NGF expression follows injury or inflammation. The factor binds to TrkA and activates 
phospholipase C (PLC) which leads to TRPV1 sensitization. NGF also increases expression and 
trafficking to the plasma membrane of TRPV1 and other nociceptive channels such as 
mechanosensitive channels (MEC), which decrease the threshold for action potential generation in 
nociceptive neurons. NGF also induces the release of pain mediators such as histamine, 
prostaglandins and NGF itself from mast cells which result in a positive-feedback loop that 
sensitizes nociceptive neurons (McKelvey et al. 2013). Image taken from Lewin et al. 2014. 
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1.2.4 Structure of NGF, TrkA and NGF-TrkA complex 
To understand the molecular mechanisms of NGF in mediating pain, it is important to 
understand the structure of NGF, Tropomyosin-related kinase A (TrkA) and the NGF-TrkA 
complex, described in Fig 5, 6 and 7.  
1.2.4.1 Structure of NGF 
The following description of the NGF follows that given by Weismann et al. (2001). NGF, 
as found in the submandibular salivary glands of mice, is a complex 7S structure, which 
consists of two copies of α-NGF, two copies of γ-NGF and a homo-dimer of βNGF. The 
stoichiometric arrangement is described as a2b2g2, around a two-fold symmetry axis 
relating the two βNGF molecules (Fig. 5A). To stabilize the a2b2g2 complex, conditions 
are created to allow two zinc ions to bind at the interfaces between the βNGF and the γ-
NGF. 
The α-NGF and γ-NGF belong to kallikrein family of serine proteases. The homo-dimer 
βNGF is the biologically-active form. The molecular weight of the βNGF monomer (Fig. 
5B) is 13 kDa. The two βNGF monomers have three di-sulphide bridges linking them. 
Each β-NGF monomer is expressed in an immature form namely, Pre-Pro peptide 
consisting of an 18 amino acid signal peptide (Pre), as well as a 103 residue Pro peptide. 
The γ-NGF is a specific protease which cleaves the Pre-Pro signal to its mature form, the 
βNGF monomer. The α-NGF is inactive and has been described as a ‘locked zymogen’. 
The importance of the Pre signal and the Pro peptide in the βNGF monomer became 
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evident in the course of this study for reasons which will be discussed in detail in Chapter 
3. The homo-dimer βNGF is referred to as NGF in the following pages of this report. 
Neurons respond to NGF via two cell surface receptors, namely TrkA and p75 (Luberg et 
al. 2015). In this study, p75 was not examined for a number reasons including the literature 
caveat that it causes cell apoptosis (Rabizadeh & Bredesen 2003). On the other hand, 
evidence from the literature intimated that TrkA receptor was responsible for cell survival 
and development (Huang & Reichardt 2003). Therefore, the experiments employed in this 
study were designed to exploit the reported benefits of TrkA. 
The signaling of NGF in nociceptor neurons is mediated through two cell surface receptors, 
namely TrkA and p75 (Luberg et al. 2015). NGF binds to TrkA with high affinity (Kd ~10
-
11
 M) by comparison with p75 (Kd ~10
-9
 M). In this study, p75 was not examined for a 
number reasons including the literature caveat that it causes cell apoptosis (Rabizadeh & 
Bredesen 2003). Instead, the experiments focused on TrkA for the following reasons: (1) 
TrkA signaling mediates neurotropic effects such as cell survival, differentiation and cell 
development. (2) NGF/TrkA signaling mediates the nociceptive functions of sensory 
neurons i.e. NGF/TrkA signaling pathway leads to the generation of action potentials for 
neuronal signaling as described in section 1.2.3  
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Fig. 5 Structure of the 7S NGF complex (PDB access code I SGF) and the NGF 
monomer (Protein Data Bank code 1BFT:  (A) 7S NGF complex with the homo-dimer of 
βNGF, depicted in red at the center, two copies of α-NGF shown in green, and two copies of γ-NGF 
in blue. (B) The secondary structure elements of NGF monomer are labelled and depicted 
according to McDonald et al. (1991). The termini as well as the loop regions, L1-L4, are labelled in 
red, and the cysteine residues forming the cysteine-knot motif near the top of the molecule are 
shown in gray and yellow in ball-and-stick rendering. Images taken from Weismann et al 2001. 
1.2.4.2  Structure of TrkA 
Three forms of Tropomyosin receptor kinase (Trk) are expressed on cell surface of host of 
cells, TrkA, TrkB and TrkC; NGF binds to TrkA with a binding affinity of 10 
-11
KD,  
whereas different growth factors bind to the others (Luberg et al. 2015).  
A B 
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Trk receptors are glycoproteins that possess an extracellular ligand-binding domain, a 
hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase domain. 
Extracellularly, Trk receptors contain an arrangement of three leucine-rich 24-residue 
(LRR1-3) motifs which are bordered by two cysteine clusters (C1 and C2), followed by 
two immunoglobulin-like domains (Ig1 and Ig2). These are followed by a single 
transmembrane and a cytoplasmic domain that consists of a tyrosine kinase and several 
tyrosine-containing motifs. Phosphorylation of the cytoplasmic tyrosine in the TrkA 
receptor, regulates tyrosine kinase activity and provides phosphorylation-dependent 
recruitment sites for adaptor molecules and enzymes that mediate initiation of intracellular 
signaling cascades (Huang & Reichardt 2003; Marlin et al. 2015, Rabizadeh & Bredesen 
2003) (Fig. 6).  
 
Fig. 6 Schematic presentation of the TrkA receptor. The three leucine-rich motifs (LRR1-
3) are flanked by two cysteine clusters (C1 and C2) and after these the two Ig domains. The 
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tyrosine kinase domain is located at the intracellular domain. Image modified from Allen and 
Dawbarn 2006.  
Resolution of the crystal structure of the NGF-TrkA complex showed that NGF engages 
with the second immunoglobulin-like domain, known as domain 5 (d5)(Fig. 6) of TrkA 
through two distinct patches. The first patch involves the four β-sheets present in the center 
of NGF molecule together with the first loop. The second patch is formed by the N-
terminus of NGF, which is important in binding to TrkA (Wiesmann et al. 1999; Butte 
2001).  
The transduction of signal between NGF-TrkA is crucial in the development and growth in 
various host cells of peripheral nervous system (Huang & Reichardt 2003), including 
sensory neurons mediating pain (Marmigère 2006), postganglionic sympathetic neurons 
(Smeyne et al. 1994) and basal forebrain cholinergic neurons (Fagan et al. 1997). NGF 
secreted by the target cell interacts with TrkA on the axonal tip. The interaction of NGF to 
the extracellular domain Ig-C2 domain of TrkA leads to conformational changes inducing 
TrkA receptor dimerization, followed by rapid transphosphorylation of five tyrosine 
residues on the cytoplasmic tail by the neighboring TrkA receptors. These phosphorylated 
sites on TrkA receptors serve as docking sites for adaptor for proteins containing 
phosphotyrosine-binding (PTB) or Sarcoma tyrosine-protein kinase (Src) homology 2 
(SH2) domains such as Shc  (Huang & Reichardt 2003). These cytoplasmic adaptor 
proteins bind to phosphorylation sites on the cytoplasmic tail where they are 
phosphorylated leading to activation of intracellular signaling pathways, Ras-mitogen 
activated protein kinase (MAPK) cascade pathway, the phosphatidylinositol-3-kinase 
(PI3K)/Akt kinase pathway and  phospholipase C γ -1 (PLC-γ1) (Huang & Reichardt 2003; 
Sanse et al. 2011; Marlin et al. 2015).  
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 The signals arising NGF/TrkA complex are transported from the tip of axons to cell soma 
and then into dendrites by retrograde transport (An axonal transport mechanism 
responsible for moving molecules destined for degradation by lysomes from the axon back 
to the cell body) by the mechanism of internalization and signaling endosome formation.  
TrkA undergoes internalization following engagement to NGF and this internalization at 
the tip of axons seems to be essential for retrograde survival signaling. Receptor-mediated 
endocytosis mechanisms can be broadly classified as being either clathrin-dependent or 
clathrin-independent, and recent findings suggest that TrkA may be internalized by both 
mechanisms. Controversy exists regarding the precise mechanism of TrkA internalization 
(Harrington and Ginty 2013; Doherty and McMahon 2009). 
 In clathrin-dependent mechanism for the endocytosis of TRKA, NGF causes a 
redistribution of the clathrin heavy chain to the plasma membrane and promotes the 
formation of protein complexes that contain TRKA, clathrin and adaptor protein 2 (AP2) 
(Doherty and McMahon 2009).  Clathrin-independent mechanism (macropinocytosis) 
underlying TRKA endocytosis involves the formation of plasma membrane protrusions 
that eventually fuse together and engulf large volumes of membrane and extracellular fluid. 
Pincher, an NGF-upregulated GTPase, is involved in this mechanism of TRKA 
internalization
 
(Harrington and Ginty 2013;Shao et al. 2002). The signaling events of both 
clathrin-mediated and pincher-mediated endocytosis for the internalization of TRKA and 
initiation of the NGF retrograde signal are poorly understood.  
As mentioned earlier in this section, three major effector pathways for TRKA are the PI3K, 
ERK and PLCγ pathways. Of these, the PI3K and PLCγ pathways have the most important 
roles in receptor internalization. PI3K is activated by TRKA via the adaptor protein GAB1 
(GRB2-associated-binding protein 1) (Harrington and Ginty 2013; Kaplan et al. 2000).  
  Chapter 1  
19 
   
PI3K itself participates in internalization and the phosophoinositide products of its 
enzymatic activity bind and regulate several proteins implicated in endocytosis, including 
dynamin Krag et al. 2010, RAS-related protein RAB5 (Harrington and Ginty 2013; 
Christoforidis et al. 1999), AP2 (Harrington and Ginty 2013; Abe  et al. 2008) and 
synaptotagmin (Harrington and Ginty 2013; Radhakrishnan  et al. 2009). Dynamin, a 
GTPase involved in pinching off the endocytic vesicle from the plasma membrane, is a 
required component for NGF–TRKA internalization and subsequent retrograde transport 
(Harrington and Ginty 2013; Zhang et al. 2000). The pleckstrin homology (PH) domain of 
dynamin is required for its function in clathrin-mediated endocytosis. This activity requires 
the binding of phosphoinostides to the PH domain (Harrington and Ginty 2013; Bethoney  
et al. 2009) . Phosphoinostides themselves participate in vesicle coat formation and vesicle 
targeting through recruitment of AP2. Thus, PI3K activity is probably required at multiple 
stages in TRK-mediated endocytosis (Harrington and Ginty 2013).  
Phosphorylation of TRKA at Tyr785 following NGF binding leads to recruitment and 
activation of PLCγ (Harrington and Ginty 2013; Vetter  et al  1991). PLCγ is a 
multifunctional enzyme, acting as both a lipase and as an interacting partner for additional 
receptor tyrosine effectors through its SRC homology domains (Harrington and Ginty 
2013; Bunney and Katan et al.  2011). The downstream effects of PLCγ can be categorized 
as those mediated by the second messengers of its lipase activity (that is, diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3)) and those mediated by direct interactions. A 
recent study found that PLCγ activity is required for ligand-mediated TRKA internalization 
(Bodmer  et al.  2011; Harrington and Ginty 2013;) possibly through the control of 
dynamin. Indeed, the release of Ca2+ from internal stores into the cytoplasm that is caused 
by PLCγ-mediated formation of IP3 activates the phosphatase calcineurin, which in turn 
catalyses dephosphorylation of key dynamin residues that are required for receptor 
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internalization (Harrington and Ginty 2013). Thus, events that are essential for different 
steps of TRK internalization are controlled by the early effectors PI3K and PLCγ 
Harrington and Ginty 2013). 
Literature evidence suggests that the NGF-TrkA complex is proposed to be sorted into 
short lived recycling endosomes or long-lived signaling endosomes. The long-lived 
signaling endosomes are proposed to promote the cell survival and differentiation signals, 
during their journey towards the somatodendritic area via the retrograde transport 
mechanism (Harrington et al. 2011; Harrington et al. 2013). The fate of endocytosed NGF-
TrkA is complex and it is unclear whether it is sorted into recycling (short lived) or long-
lived signaling endosomes (Marlin et al. 2015). This ability of NGF-TrkA complex to be 
sorted into endosomes may enable the LC of BoNT/A to be targeted to sensory neurons 
(see later). Exploitation of this is the key objective of this study 
.
 
 
 
 
 
 
 
 
A 
B 
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Fig. 7 NGF - TrkA complex A) Sequence of events when NGF binds to TrkA. The biologically 
active forms of βNGF are dimers of identical 13 kDa peptide chains. The βNGF dimer binds to the 
TrkA protein. The binding induces two TrkA receptors to dimerize. This NGF-TrkA complex leads to 
transphosphorylation of five tyrosine residues on the cytoplasmic tail of the adjacent TrkA receptor. 
The cytoplasmic adaptor proteins such as Shc) bind to specific phosphorylation sites on the 
cytoplasmic tail where these substrates are phosphorylated. The bound adaptor proteins provide 
docking sites for downstream signaling proteins PI3 Kinase and PLC- γ1. Image adapted from 
Sanes et al. 2011. (B) Mechanisms of neurotrophin internalization, signalling and retrograde 
transport. (a) It has been proposed that internalization of tropomyosin receptor kinase A (TRKA) 
following binding to nerve growth factor (NGF) occurs through clathrin-dependent and clathrin-
independent mechanisms. Although clathrin-mediated endocytosis results in the formation of early 
endosomes, internalization via macropinocytosis leads to the generation of multivesicular bodies. 
(b) Newly internalized TRKA endosomes must overcome an F-actin barrier before docking with 
microtubules for long distance transport. This is achieved by activation of RAS-related C3 
botulinum toxin substrate 1 (RAC1), which leads to actin depolymerization through recruitment of 
cofilin to the signalling endosome. (c) TRKA endosomes that are competent for transport are linked 
to the retrograde motor protein dynein and move towards the neuron’s soma. Signalling from the 
phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase (ERK) and 
phospholipase Cγ (PLCγ) signalling pathways persists during endosome transport. The specific 
RAB composition of these endosomes remains controversial. DAG, diacylglycerol; GRB2, growth 
factor receptor-bound protein 2; IP
3
, inositol 1,4,5-triphosphate; SOS, son of sevenless. Imahe take 
from Harrington and Ginty 2013. 
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 Chronic pain management 1.3
The prevalence of chronic pain in modern societies has been discussed in the preamble to 
this chapter and the cost, in terms of quality of life and the drain on the exchequer, 
indicated. The need for governments to address the relevant issues through adequate and 
fit-for-purpose health services has been noted. In general, the treatments currently applied 
focus on pharmacological methods on the one hand and, on the other, education programs 
to inform healthy lifestyle decisions. 
1.3.1 Current pharmacological treatment and limitations 
The most commonly prescribed drugs for chronic pain in 15 European countries reported 
by Breivik et al. 2006 were NSAIDs (Nonsteroidal anti-inflammatory drug) (44%), weak 
opioid analgesics e.g. codeine (23%), paracetamol (18%) and strong opioid analgesic e.g. 
morphine (5%). Out of the 124 from UK and 129 from Ireland, 12% and 13 % used strong 
opioids. Kalso et al. 2003 and the pain society (2004) provided comprehensive guidance on 
the use for opioids to non-cancer-related pain.  
Combating the side effects of medication is a matter of urgent concern. Much of the 
literature supports the view that, despite significant advances in the understanding of the 
pathophysiology of chronic pain (Gold et al. 2010) its management continues to challenge 
physicians and fails to serve patients. Breivik et al. 2006 reported that NSAIDs have 
adverse effects on the cardiovascular, and the gastrointestinal system where an overdose of 
paracetamol, for example, has the risk of hepatotoxicity. Their study highlighted that all 
analgesics have side effects including stomach upset, constipation, diarrhea, dizziness, or 
headache. Stannard and Johnson, 2003 reported that over one-third of respondents were 
concerned about the dangers of becoming addicted to pain medications and the remaining 
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two third expressed concern about other side effects. On the other hand, 64 % of 
respondents to one study of chronic pain patients using prescribed pain medications 
reported that they were inadequate to control their pain (Breivik et al. 2006). They also 
reported that 74% of GPs in the UK cited side effects of drugs as a major barrier to pain 
control.  
Whelton et al. 2000 and Benyamin et al. 2008 give further examples of the need to address 
the side effects and risks of analgesic drugs in clinical practice. It is accepted that, as stated 
by Manthy et al. 2011, there are very few treatments that efficiently regulate chronic pain 
without unwanted side effects. The work reviewed in this report sought to maximise the 
wanted and minimise the unwanted side effects of pain killers. Currently, international best 
practise guidelines recommend a multimodal combination of pharmacologic and non-
pharmacological modalities as the most effective strategy to manage the disability 
associated with chronic pain (Kimura et al. 2010). The approach used in this study focuses 
on the pharmacological ones. There are unmet needs which require the advancement of 
drug discovery research dealing with chronic pain for development of new class of drugs 
with long-lasting effect and which do not contribute towards side effects like drug 
dependence. 
This study describes a new approach that seeks to exploit the ability of BoNT/A in the 
management of pain. Therefore, it is important to understand its structure and its role in 
blocking the exocytosis mechanism. This is illustrated in the next section. 
1.3.2  Botulinum toxin type A as an emerging therapeutic 
Since approval of Botox
®
 in 1989 in the United States, Allergan has confirmed its safety as 
a therapeutic for the treatment of strabismus, benign essential blepharospasm and 
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conditions of the VII
th
 nerve. As demonstrated by fluorescent immuno-microscopy in a 
study of rodent nerve-muscle preparations paralysed with BoNT/A, its ability to 
accumulate the mediator Calcitonin gene-related peptide (CGRP) in the pre-synapse 
presented the first clues to its potential benefits in pain (Lande et al. 1989). Further 
evidence of pain relief was provided by successful treatment of dystonia patients with 
intra-muscular injections of BOTOX
®
 (Brin et al. 1987).  In the treatment of migraine, the 
injection of BOTOX
® 
caused a reduction in the severity and the frequency of migraine 
episodes (Binder et al. 1998). Its success has encouraged a new interest in BoNT as a 
potential anti-nociceptive. A study of 30 migraine suffers revealed that BOTOX
®
 treatment 
of any severity of migraine was well tolerated and that it relieved in a significant manner 
the frequency of migraine attacks at day 90, and the frequency of severe attacks at day 60 
and 90 (Barrientos and Chana, 2003). In a study to discover its success in treatment of 
chronic tension type headaches, local injections of BOTOX® resulted in less headaches 
and precranial muscle tenderness (Relja and Telarovic, 2004). In a study on 29 patients 
with focal painful neuropathies and mechanical allodynia, BOTOX
®
 resulted in a direct 
pain-killing effect on muscle tone of these subjects (Ranoux et al. 2008). Their effect on 
refractory neck pain was investigated on 47 subjects, showing a significant decrease in the 
mean pain intensity (Miller et al. 2009). More recently (Diener et al. 2010), in a large trial 
with 1384 chronic migraine suffers treated with onabotulinumtoxinA (BOTOX
®
), the 
results showed after one dose the occurrence of headache days was significantly reduced 
and this benefit lasted for six months. Following such encouraging results from these 
clinical studies, Allergan Inc. was granted approval by the FDA  and MHRA for BOTOX
®
 
as a treatment for chronic migraineuers (headaches for 15 days or more per month) in the 
United States and UK, respectively (Aoki and Francis, 2011). BoNT have been exploited 
as muscular relaxant and in treatment of chronic pain. Because this study exploits the 
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ability of BoNT/A in the management of pain, it is important to understand the structure 
and the mechanisms of BoNT. 
1.3.3 Botulinum neurotoxin 
Botulinum neurotoxin (BoNT) is produced from Clostridum botulinum, a rod shaped gram-
positive bacterium which grows in anaerobic conditions (Karalewitz et al. 2012). BoNT 
causes flaccid paralysis or botulism. Clostridium botulinum was cultured and isolated 
successfully in 1944 by Edward Schantz. Its success in the blocking of neuro-muscular 
transmission was reported by Burgen in 1949. In the last decade, BoNT/A research has 
gained considerable pace because of its impact on public health, potential utilization as a 
bio-terrorist molecule, and clinical applications in medical industry (Poulain et al. 2008). 
Seven categories of BoNTs from A-G, all of which are toxic to non-human primates have 
been identified, described and reviewed (Poulain et al. 2008). Type A toxin is the most 
broadly studied and applied for therapeutic treatments (Davletov et al., 2005; Foran et al., 
2003; Jankovic, 2004).   
1.3.3.1 Structure 
BoNT/A consists of three independent functional domains, namely, (1) a heavy chain C-
terminal domain which binds to the acceptors (HC), described below. (2) a translocation 
domain (HN). (3) a light chain which is a zinc-dependent catalytic endopeptidase (LC) (Fig. 
8). The 150k single-chain BoNT/A becomes activated upon proteolysis by endogenous 
bacterial proteases (or by trypsin when proteolysis is carried out in vitro). Proteolysis leads 
to di-chains of HN.HCN.HCC and LC, linked via a disulphide bond and non-covalent 
interactions. The molecular weight of each of the three BoNT/A domains is ~50 k. The C-
terminal acceptor-binding (HC) domain is sub-divided further into two structural domains: 
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C terminal domain (HCC) and N terminal domain (HCN). Both play an important role in 
binding to gangliosides and high affinity protein synaptic vesicle protein (Chai et al. 2006; 
Jin et al. 2006). The N terminus of the HC (HCN) appears to form jelly-roll folds similar to 
legume seed lecithin-like structures (L-type lecitins) and the C-terminus of HC (HCC) 
appears to form a β-trefoil fold similar to ricin–type lectins (R-type) (Karalewitz et al. 
2012; Varki et al. 2009; Thomas et al. 2009). HCN consists of a series of anti-parallel 
strands, which are connected by short loops, to form two β-sheets (Karalewitz et al. 2012). 
The function of HCN was reported to facilitate neurotoxin entry in co-ordination with HCC. 
However, its independent function is unclear (Rummel et al. 2011). The HCC is known as 
the receptor binding domain, which binds to gangliosides and protein acceptor contributing 
to neuronal tropism of BoNT/A (Karalewitz et al. 2012). An engineered variant of 
BoNT/A∆HCC lacking the HCC domain of BoNT/A created in ICNT displayed a greatly 
decreased ability to enter neurons isolated from the dorsal root ganglia (unpublished data). 
This has been exploited in this study as a control in the experiments described in Chapter 3. 
It is reported that HN consists of long helices which appears as a tunnel via which the LC 
passes into the neuronal cytosol (Fischer et al. 2007, Fischer et al. 2009). The LC is a zinc 
dependent metalloprotease, which cleaves SNARE proteins. LC is joined to HN by a 
disulphide bond and non-covalent interactions by a loop from HN, referred as the belt, 
around the LC region (Karalewitz et al. 2012). The literature provides evidence on 
recombinant variants of LHN, described later in this chapter. Because this report focuses on 
BoNT/A and its entry into motor neurons leading to the blockage of neurotransmission 
signal, a description of the exocytosis mechanism follows.  
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Fig. 8 BoNT/A (a) Schematic of BoNT/A. (b) Structure of BoNT/A. Proteases cleave BoNT into 
their active forms which consists of a Mr ~100 k heavy chain (HC) and a Mr ~50 k light chain (LC) 
linked by a disulphide and non-covalent bonds.  The HC region is important for binding to 
gangliosides and protein acceptor, the HN for translocation and the LC for protease activity. Image 
taken from Dolly and O'Connell (2012). 
1.3.3.2  Exocytosis mechanism 
The fusion of an intracellular trafficking vesicle with the plasma membrane is described as 
exocytosis. It plays a crucial role for growth and differentiation because it is the only 
mechanism whereby a cell can add additional membrane to the plasmalemma (a semi-
permeable membrane enclosing the cytoplasm of a cell). Exocytosis regulates delivery of 
secretory products such as neurotransmitters, transporters, enzymes, or channels. At the 
molecular level, exocytosis involves specialized protein families such as the SNAREs, the 
Rab/ypt proteins, and the Sec1/Munc18-like (SM) protein family. Because of the relevance 
of SNAREs to this study, their role in exocytosis is described below (Jahn et al. 2004).  
SNAREs represent membrane-anchored proteins and are crucial for intracellular fusion 
events (Jahn et al. 2003; Jahn et al. 1999; Rizo et al. 2002; Fasshauer et al. 2003). 
  
HC LC 
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SNAREs referred   to in this study include 1) the syntaxin-1 and 2) SNAP-25, localized on 
the plasma membrane, and 3) the synaptobrevin (also known as Vamp), concentrated on 
the membrane of synaptic and neurosecretory vesicles.  
SNARE motifs show a tendency to homo-oligomerize into helical bundles (Fig 9). 
Literature suggests that during neuronal exocytosis, a synaptosomal associated protein with 
molecular weight 25 kDa (SNAP-25) is commonly bound on the plasma membrane due to 
various palmitoyl chains that include cysteine amino acids. Syntaxin-1 and Vamp, on the 
other hand, are bound on plasma and synaptic vesicle membranes, respectively, via their C-
terminal domains (Foran et al. 2003; Humeau et al. 2000; Yamasaki et al. 1994). From the 
combination of syntaxin-1, Vamp and SNAP-25, a tight SNARE complex emerges, 
represented by elongated bundles of four α helices each of which is contributed by one of 
the participating SNARE motifs (two from SNAP-25), with the transmembrane domains 
being located at one end of the bundle (Hanson  et al. 1997;Sutton et al. 1998). The core of 
the bundle consists of the helices, connected by 16 layers of hydrophobic amino acid side 
chains. The assembled SNARE complex is stable and resistant to treatment with the 
detergents sodium dodecyl sulfate (Hayashi et al. 1995; Fasshauer et al. 2002), a property 
exploited for bi-chemical coupling of recombinants (Darios et al. 2010) described in 
Chapter 3. Formation of the SNARE complex is triggered by Ca
2+ 
at micro-molar 
concentrations (Rizzo et al. 2002). In addition to the three SNARE proteins, a large 
number of accessory proteins exist that enhance the SNARE-driven exocytosis process 
(Barclay et al. 2005).  
A Ca2+
 
sensor namely, synaptotagmin interacts with SNAP-25 in early synaptic vesicle 
docking within the presynaptic membrane. The C-terminal cytoplasmic region of 
synaptotagmin binds to Ca2+
 
and its N-terminal domain is present within the lumen of pre-
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synaptic vesicle (Littleton et al. 2001). Upon binding to Ca2+, synaptotagmin facilitates the 
Ca2+-evoked synaptic vesicle fusion with the presynaptic membrane (Humeau et al. 2000). 
Truncation caused by cleavage of the SNARE proteins by BoNTs prevents the formation 
of SNARE complex (Fig.9) and inhibits exocytosis. 
 
 
 
 
 
 
 
 
 
Fig.9 SNARE complex and synaptotagmin driven exocytosis. (A-C) represents topology 
and organization of the synaptic fusion complex. (A) Showing backbone ribbon structure of 
neuronal SNARE core complex. Synaptobrevin 2 (Sb) is shown in blue; Syntaxin 1 (Sx) is in red; 
and SNAP-25 (Sn1 and Sn2) is in green. (B) Organization of the SNARE core complex shows 15 
hydrophobic layers and 1 ionic “0” layer. Cα traces (grey), local helical axes (blue, red and green 
for synaptobrevin-II, syntaxin-1A and SNAP-25B, respectively), the super-helical axis (black), and 
layers refer to the C carbons that are closest to the center of the four helix bundle (0, red;-1, +1 
and +2, blue; all others black; layer numbering is centered at the ionic layer) are shown for one of 
the three complexes in the asymmetric unit. (C) The structure of the central ionic “0” layer of the 
C D 
A 
B 
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synaptic fusion complex. Side chains involved in the layer are shown as balls and sticks; backbone 
is shown as a ribbon. The total buried surface area for the sidechain atoms in this layer is 742A° 
(Picture is adapted from Sutton 1998) (D) The core of SNARE complex consists of α-tetra helices; 
two from SNAP-25 and one each from Vamp and syntaxin-1; synaptotagmin (Ca
2+ 
sensor) that 
maintains SNARE zipping and vesicle fusion. Synaptotagmin consists of an N-terminal 
transmembrane region and two C-terminal domains namely, C2A and C2B, which bind to 
Ca
+2
(Image is adapted from Carr and Munson, 2007). 
1.3.3.3  Blockage of the exocytosis mechanism  
There are four steps (Fig. 10A) by which BoNTs causes blockage of the exocytosis 
mechanism, namely, 1) the binding domain (HC) attaches to the ecto-acceptors on 
cholinergic nerve terminals, 2) acceptor-mediated endocytosis and 3) translocation of a 
zinc-dependent catalytic endopeptidase LC 4) cleavage and inactivation of protein(s) 
essential for neurotransmitter release (Dolly and Lawrence 2014). 
Specifically in relation to BoNT/A mechanisms, on entry into the neuronal cytoplasm, the 
zinc dependent LC/A selectively cleaves 9 amino acids from the C-terminal of SNAP-25. 
As already mentioned cleavage of SNAP-25 blocks the fusion of small clear synaptic 
vesicles (SCSVs) and large dense-core vesicles (LDCVs) to the plasma membrane and 
thereby blocks the exocytosis of neurotransmitters (Black and Dolly 1986; Dolly et al. 
1984; Dolly et al. 1994; Humeau et al. 2000; Schiavo et al. 2000; Simpson 1979, Simpson 
et al. 1981).  
Step 1: binding to the ecto-acceptors 
BoNT/A recognizes cholinergic neurons by its HCC, ganglioside and synaptic vesicle 
protein binding domain (Baldwin et al. 2007, Emsley et al. 2000, Shapiro et al. 1997, 
Rummel et al. 2004, Stenmark et al. 2008, Chai et al. 2006, Jin et al. 2006). Yowler et al. 
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2004 suggest that HCC of BoNT/A binds to gangliosides and glycosphingolipids 
predominantly found in the plasma membrane of cholinergic motor neurons. There is 
evidence (Emsley et al. 2000, Shapiro et al. 1997, Rummel et al. 2004, Stenmark et al. 
2008) that a conserved ganglioside binding region, consisting of amino acid residues 
starting with Histidine and ending with Tyrosine ‘HSXWY’ exists within the HC of 
BoNT/A. This conserved region is also known as the ganglioside binding pocket (GBP). 
Amino acids H and W are in direct contact with the ganglioside. On neuronal stimulation, 
the C-terminal end of HCC, beside the GBP, facilitates the interaction of HC with a second 
receptor namely, synaptic vesicle protein (Chai et al. 2006; Jin et al. 2006). 
Step 2: acceptor-mediated endocytosis 
Literature evidence suggests that BoNT/A binds with high affinity to synaptic vesicle 
protein 2 (SV2). After binding to the surface, BoNT/A is internalized by SV2 endosome 
recycling. SV2 is reported as an integral membrane glycoprotein with three isoforms 
namely, SV2A, SV2B, and SV2C. SV2A is predominantly found throughout the nervous 
system. Whilst SV2C is reported in neurons of some brain areas, very little is known about 
SV2B in the literature (Bajjalieh et al. 1994; Bajjalieh et al. 1993; Janz et al. 1998; Janz 
and Sudhof, 1999). 
Step 3: translocation of a zinc-dependent catalytic endopeptidase LC 
The low pH environment of endosomes (due to the proton pumps present in the 
endosomes), leads to conformational changes of BoNT/A during which the HN forms a 
membrane pore through which the LC passes and escapes from the endosome into the 
cytosol (Koriazova et al. 2003) (Fig. 10B).  
Step 4: cleavage and inactivation of protein(s) essential for neurotransmitter release. 
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After entry into the neuronal cytosol, LC specifically cleaves either vesicle or plasma 
membrane SNAREs. The LC of different serotypes of BoNTs has varied SNARE 
preferences. The literature review highlighted that SNAP-25 is cleaved by LC of BoNT/A, 
C1 and E. Syntaxin IA/IB is reported to be also cleaved by LC of BoNT/C1 (Wang et al. 
2011) and Vamp isoforms 1, 2 and 3 are cleaved by LC of BoNT/B, /D, /F and /G (Foran et 
al. 2003; Humeau et al. 2000; Yamasaki et al. 1994). The resultant effect of LC cleavage 
of SNARE proteins leads to blocking of the exocytosis mechanism, which stalls the neuro-
muscular communication causing flaccid paralysis (Poulain et al. 2008, Chen et al. 2011, 
Schiavo et al. 1992). It must be noted that only BoNT/A experiments were carried out in 
this research, in which the cleavage of SNAP-25 by BoNT/A was exploited. The results of 
these 
experiments 
are presented 
and discussed 
in Chapter 3 
and 4, 
respectively. 
Fig 10. 
BoNT/A 
block 
exocytosis at 
neuro-
muscular 
junction (NMJ). A) BoNT/A blocks the release of transmitters via a multi-phasic mechanism 
culminating in the cleavage/inactivation of intraneuronal SNAP-25. Involving step 1 - acceptor 
binding, step 2 -  endocytosis, step 3  -  escape pf LC from the endosome and step 4  SNARE 
A 
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cleavage B) Suggested mechanism of translocation of the light chain, adapted from Fischer et al. 
2007. Image taken from Dolly and Lawrence 2014.  
1.3.3.4 Applications of re-engineered BoNT/A  
The modular arrangement of BoNT and the independent functions of its three domains 
have encouraged several researchers to create variant BoNTs, using recombinant DNA 
technology (a common feature among all seven serotypes of BoNT) (Chen 2012; Masuyer 
et al. 2014). Natural variants of BoNT/A like subtype BoNT/A2 composed of LC of 
BoNT/A1 and HC of BoNT/A3 (Arndt et al. 2006) are formed due to natural genetic 
recombination process which, furthermore, encouraged researchers to exploit protein 
engineering technology. Literature (Chen 2012, Masuyer et al. 2014) suggests that with the 
help of genetic engineering technology, researchers had particularly identified various 
therapeutic applications of BoNT/A. They explored the following functional characteristics 
of BoNT/A to enhance its:  
i. Neurotoxin activity 
ii. Potential as a neurotoxin transporter 
iii. LCHN fragment 
a. Ability of LCHN to act as targeted secretion inhibitor 
b. Ability of  LCHN to assemble into a functional molecule via protein stapling 
technology 
1.3.3.4.1  Neurotoxin activity 
Neurotoxin activity of BoNT/A relates to its ability to enter neuronal cytosol, cleave 
SNAP-25 and block the exocytosis of neurotransmitter. Literature describes that the 
intracellular speed of translocation of BoNT is dependent on the translocation domain 
(HN), while its potency and toxicity are directly related to LC (Wang et al. 2008). The 
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literature argues that both, BoNT/A and BoNT/E cleave SNAP-25, but the latter by 
comparison to the former was faster and more potent in blocking the neurotransmission but 
for a shorter duration of time (Wang et al. 2008; Foran et al. 2003). While acknowledging 
the advantages of BoNT/E, the longer duration of BoNT/A neurotoxin activity determined 
the decision to exploit in this study, its use in the cleavage of SNAP-25.  
Researchers focused on using protein engineering to improve the stability of LC/A after 
translocation step, for long-lasting effect in cleaving SNAP-25. Wang et al. 2008 
demonstrated that the C-terminal end dileucine plays an important role in persistent SNAP-
25 cleavage, and mutations of these residues shorten the direction of SNAP-25 cleavage.  
Tsai et al. 2010 showed that, by comparison to LC/A, the ubiquitin-proteasome facilitates 
the degradation of LC/E via the ring finger protein TRAF2; they suggested that LC/A was 
not targeted by the ubiquitination degradation pathway which make them an ideal tool for 
therapeutic application.  
1.3.3.4.2  Botulinum neurotoxin as a transporter 
The HC (binding domain) specifically binds to neuronal targets and allows the entry of 
BoNT/A into the neuronal cytosol. BoNT/A HC domain as a protein transporter was 
reported by Drachman et al. 2010, who exploited the conjugating property of biotin and 
streptavidin. Drachman et al. 2010 illustrated a method in which HC of BoNT/A linked to 
streptavidin, allows targeting of biotinylated viral vectors into neuronal cells. They 
reported that this design had the potential for treating muscular neuropathies including, 
spinal muscular atrophy and amyotrophic lateral sclerosis, as the biotinylated viral vectors 
carried therapeutic genes inside the motor nerve cells. 
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1.3.3.4.3 The LCHN fragment 
Shone et al. (1985) demonstrated that controlled proteolytic digestion of BoNT/A by 
trypsin results in the di-chain of LC/A and HN linked by di-sulphide bond, named LCHN/A 
fragment, lacking the binding domain (HC). By replacing the HC with alternative ligands, 
the LCHN/A fragment has been targeted to various neuronal and non-neuronal cells, 
blocking secretory functions of that targeted cell via the cleavage of SNAP-25  (Foster, 
Hambelton, & Clifford, 2006; Foster 2009). 
1.3.3.4.3.1 Ability of LCHN/A to act as targeted secretion inhibitors 
In the last 15 years, researchers have explored chemical conjugation as a method to couple 
LCHN/A fragment to various ligands, to develop targeted secretion inhibitors. Chaddock et 
al. 2000a were the first to describe a method for chemically conjugating LCHN/A with 
NGF. They reported the retargeting of LC/A to neuro-endocrine cells like PC-12 cells, 
which led to inhibition of noradrenaline release due to the cleavage of SNAP-25. Chaddock 
et al. 2000b described the chemical conjugation of LCHN/A to wheat germ agglutinin 
(WGA), and reported the delivery of the endopeptidase into several neuronal and non-
neuronal cell types. They reported that LCHN/A was responsible for the inhibition of 
neurotransmitter secretion in neuronal cells, and attenuation of insulin secretion from 
pancreatic cells.   
Darios et al. 2010 described that issues such as poor yield and high cost in preparing large 
quantities of coupled product, led them to the discovery of protein stapling technology. 
This technology, illustrated in fig 22, has the potential to surpass the obstacles arising from 
recombinantly-engineering BoNT/A such as large size, its dependence on additional 
structural units for translocation into the neuronal cytosol, and its variable production 
yields. Of particular interest to this study was the reported ability of this technology to 
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address issues of poor yield and inactive protein. How this was exploited in this study is 
described in detail in Chapters, 3 and 4. 
1.3.3.4.3.2 Ability of LCHN to assemble as a functional molecule via protein 
technology 
The literature describes the term ‘protein stapling’ to indicate fusion of two proteins into a 
single polypeptide chain by recombinant means or chemically cross-linked. This study 
refers to the term ‘protein stapling technology’ with regards to a new linking method 
described by Darios et al 2010. This method is based on two distinct polypeptide linkers 
which self-assemble and stabilize a given protein conformation in the presence of a 
specific peptide brace (staple) (Ferrari et al. 2012). 
As described in section 1.3.3.2, during neuronal exocytosis, synaptic vesicles bind to 
SNARE to form a tight tetra helical complex. Protein stapling technology exploits the self-
assembling property of three helical SNAREs such as SNAP-25, Vamp and Syntaxin - 1 to 
form a tight tetra-helical protein complex. Of the four helices in the complex, SNAP-25 
contributes two domains, syntaxin-1 contributes one domain and Vamp contributes one 
domain.  
Darios et al. 2010 was the first to exploit this tight interacting property of helical SNAREs 
to combine HC of BoNT/A and LCHN/A fragments. They recombinantly created individual 
components of both HC/A fused Vamp and LCHN/A fused SNAP-25 and combined them 
in presence of syntaxin-1 to form a fully-functional molecule, which showed cleavage of 
intra-neuronal SNAP-25. This activity was found to act similarly to native BoNT/A. 
Arsenault et al. 2013 used this concept and described and designed novel chimeric 
BoNT/A variants where the LC/A was linked to a selection of ligands to target 
neuroendocrine tumor cells. They suggested that in this approach new ligands can 
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substitute the botulinum receptor-binding domain (HC) and allow targeting of LC/A to 
distinct neurons and cells of neuroendocrine origin. Of particular interest to this study was 
a design in which individual helical SNARE fused proteins like SNAP-25 (22-206) fused 
LCHN/A and Vamp2 (25-84) fused to epidermal growth factor (EGF) were created. In the 
presence of syntaxin-1 (1-45), a stapled protein complex of EGF fused LCHN/A could be 
formed. In this way, the endopeptidase of BoNT/A was delivered into the neuroblastoma 
SH-SY5Y cells, which blocked neuroendocrine secretion due to cleavage of SNAP-25. The 
relevance of protein stapling technology to this study is discussed in detail later in Chapters 
3 and 4. 
 Aim of this study  1.4
The original aim was to develop a strategy to generate a new generation of bio-therapeutics 
to alleviate pain. This was to involve the targeting of SNAP-25, in the hyperactive sensory 
nerves, with a conjugate of NGF and LC protease of BoNT/A. As time progressed, the 
research began to converge on the creation of biologically-active βNGF.Vamp2 using 
protein stapling technology. It was decided to leave the conjugation of βNGF.Vamp2 with 
SNAP-25.LC.HN as future work.  
This study involved gaining competence in a number of related areas as stepping stones 
towards the objectives stated above. The process required familiarization with the relevant 
literature and laboratory skills like cell culture and maintenance of cells, vector creation 
using genetic engineering, protein expression, purification and testing of recombinant 
proteins on model cells 
. 
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2 Materials and Methods  
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2.1.1 Antibodies 
Item  1O/2O  
Ab  
Catalogue 
number  
Supplier  Species 
raised 
in  
WB  
dilution  
IHC 
dilution  
SNAP-25 (binds to 
amino-terminal of 
the C-terminal 
peptide). 
1O  SMI81 Sternberger Monoclonals 
Inc.   
Mouse 1:1000  1:1000 
NGF (binds to 
mouse 2.5S NGF 
Accession P01139) 
1O  AN240 Alomone Labs Ltd.  Rabbit  1:200  N/A 
LC/A (binds to N-
terminal  of LC/A) 
1O  Evorequest  Allergan Inc.  Rabbit  1:1000 N/A 
Vamp 1, 2, 3 (binds 
to the rat 
recombinant 
cellubrevin 1 – 81 
at the cytoplasmic 
part). 
1O  104102 Synaptic Systems  Rabbit   1:5000  1:500  
p44/42 MAPK or 
Erk1/2 (binds with 
1O 9102 Cell Signaling Systems Rabbit 1:1000 1:250 
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specificity and 
sensitivity to p44/42 
MAPK (Erk1/2)  
Phospho-p44/42 
MAPK or Erk1/2 
(binds specifically 
with high activity to 
Phospho-p44/42 
MAPK (Erk1/2) 
residues 
Thr202/Tyr204) 
1O 9101 Cell Signaling Systems Rabbit 1:1000 1:100 
TrkA (binding to rat 
TrkA extracellular 
domain) 
1O   N/A Provided by Louis 
Reichardt (University of 
California, San Francisco) 
Rabbit  1:1000  1:5000 
Anti-mouse Alexa-
488  
2O  A21121  Bio-Sciences Ireland Ltd Goat  N/A 1:500  
Anti-rabbit Alexa-
568  
2O  A11011  Bio-Sciences Ireland Ltd.  Goat  N/A 1:500  
Anti-rabbit-HRP  2O  711-035-
152  
Jackson Immuno research 
Europe Ltd.  
Donkey  N/A 1:5000 
Table 1 Primary and secondary antibodies.  
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2.1.2  Purchased reagents 
Name Supplier  
pET32b expression vector  Novagen 
E. coli Origami B  Novagen 
PC-12 cells American Type Cell Culture 
Collection (ATCC) 
SH-SY5Y cells Dr. Hans-Georg König 
Laboratory (Royal College 
of Surgeons, Dublin). 
Restriction enzymes  New England Biolabs 
TALON® superflow resin  Clontech 
UNO S1 and Q1 columns  Invitrogen 
Bradford protein assay kit Invitrogen 
Precision plus™ all blue protein standards Invitrogen 
 AccuPrime™ Pfx DNA polymerase Invitrogen 
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Precast gels and reagents for SDS-PAGE  Invitrogen 
PD-10 desalting columns  GE Healthcare 
Substrates for ECL detection of horseradish peroxidase  Millipore 
Enhanced chemiluminescence (ECL) reagents  Amersham (Millipore) 
Immobilon™ PVDF membrane (0.45μm) Merck Millipore 
Bicinchoninic acid (BCA) protein assay kit  Pierce 
Precast Bis-Tris gels Invitrogen 
Trypsin Sigma 
Trypsin inhibitor Sigma 
6'-Diamidino-2-phenylindole (DAPI) Sigma 
Isolectin B4-FITC Sigma 
Coomassie brilliant blue G 250 Sigma 
Benzonase nuclease Sigma  
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Leibowitz’s L15 medium Sigma 
Dulbecco’s modified Eagle’s medium (DMEM) Sigma 
Roswell Park Memorial Institute 1640 (RPMI– 16) culture medium Sigma 
1:1 mixture of DMEM and Ham’s F12 (DME F12) Sigma 
Fetal bovine serum Sigma 
Horse serum Sigma 
Poly-L-lysine  Sigma 
Laminin  Sigma 
Antibiotics (100 units/ml penicillin, and 100 μg/ml streptomycin) Sigma 
GlutMax I Sigma 
Mouse nerve growth factor (NGF-7S) Sigma 
Sodium acetate (3M), pH5.5 Sigma 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Sigma 
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Propan-2-ol Sigma 
Collagenase I, Dispase II and DNase I Roche Inc. 
Sterile cell culture plates (including 6, 12 and 24 well plates etc.) Sarstedt 
Sterile flat bottom flasks (including T-25, T-75, T-125) Sarstedt 
Sterile pipettes (including 1ml, 5 ml, 10ml and 25 ml) Sarstedt 
Rat tail derived collagen  Thermo Fisher Scientific 
Trypan blue solution 0.4% Thermo Fisher Scientific 
Miris transIT-LTI Mirus Bio LLC 
Ni-NTA super-flow resin Qiagen  
Thrombin  Merck Chemicals  
Restriction endonucleases New England Biolabs 
1X DNA loading buffer New England Biolabs 
1 Kbp DNA ladder New England Biolabs 
Table 2 Reagents used for protein expression, purification and cell culture 
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2.1.3  Prepared reagents 
Name Recipe 
4X Sample buffer (100ml) 0.8% (8g) SDS;4 m1 0.25 M Tris pH8.8 (10 ml of 
1M);4 ml Glycerol; 1 ml 0.1 %(w/v) bromophenol 
blue; β-mercapthenol 5-10% (v/v) or 200mM 1,4-
dithiothreitol (DTT) 
PMSF 1M (174.19 g) soluble to  2-propanol (half-life 100µM 
PMSF at 25◦C is, 110 min at pH 7/55 mins at pH 7.5/ 
35 mins at pH 8) 
Paraformaldehyde 4% paraformaldehyde, 1 N NaOH until solubilized, 
add 10% 10X PBS.  
1000X trace metals mixture 50mM FeCl3 (1.3g/100ml), 20mM CaCl2.2H2O 
(0.222g/100 ml), 10 mM MnS04. H2O (0.198 
g/100ml), 10mM ZnSO. 7 H2O (0.288 g/100ml), 
CoSO4 .7H2O (0.048 g/100ml), Cu SO4. 5H2O 
(0.034g/100ml), NiCl2. 6H2O (0.048g/100ml) 
20X SDS-PAGE running buffer (NuPAGE 
MOPS) – 1L 
50 mM MOPS (209.2 g), 50 mM tris Base (121.2 g), 
0.2% SDS (10 g), 1 mM EDTA (6.0 g) pH 7.7 
1X SDS-PAGE running buffer (NuPAGE 
MES) – 1L 
50 mM MES (9.769 g), 50 mM tris base (6.069 g), 
0.1% SDS (1 g), 1 mM EDTA (0.3 g) pH 7.3 
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Western blot 10X transfer buffer stock  - 1 L 30.3g tris base, 144.1 g glycine 
Western blot 1X transfer buffer 100 ml of 10X stock, 500ml H2O, 200ml methanol 
10X tris acetate EDTA buffer (agarose gel 
electrophoresis) 
48.5g Tris, 11.4 ml acetic acid and 20 ml of 0.5m 
EDTA at pH 8 (18.6g in 100 ml of distilled water) 
Phosphate buffer saline (10X) stock – 1 L 80 g NaCl, 2 g KCl, 14.4g Na2HPO4, 2.4 g KH2PO4  
Phosphate buffer saline Tween -20 (10X) 
stock – 1 L 
80 g NaCl, 2 g KCl, 14.4g Na2HPO4, 2.4 g KH2PO4, 
1g Tween-20  
Sterile1X phosphate buffer saline – 1 L 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl. 100 
ml 10 X Stock. 20 min, 121◦C, liquid cycle. 
Table 3 Reagents prepared in the lab 
 Methods 2.2
2.2.1  Molecular biology 
Standard methods were used in this study as described in Gallagher (2011) and Sambrook 
et al. (1989). 
2.2.1.1 Isolation of plasmid DNA  
Luria Bertani (LB) medium with appropriate antibiotics were inoculated with a single 
colony of E.coli and grown by shaking at 220 revolutions per min (rpm) overnight at 37
◦
 C. 
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Cells were centrifuged at 1000 x g. Plasmid DNA was isolated by using Qiagen
®
 plasmid 
mini kit. This involves alkaline lysis of cells, followed by binding of plasmid DNA to an 
anion exchange resin under appropriate low salt and pH conditions, as per manufacturer’s 
protocol. The DNA pellet was washed two times with 70% ethanol and dissolved in 30 μl 
sterile deionized water (D/W). 
2.2.1.2  DNA manipulation 
2.2.1.2.1  Restriction digestion 
Restriction digestion of plasmid DNA (~5 μg) was completed using appropriate buffer and 
20 units of enzyme per μg DNA. The samples were incubated, as instructed in the protocol 
provided by New England Biolabs.   
2.2.1.2.2 Agarose gel electrophoresis 
Agarose gel was prepared (0.7%-1%) by melting agarose in 1X Tris acetate EDTA pH 8 
(TAE); 1 in 1000 (dilution factor) of ethidium bromide was added to make up final 
concentration of 250 ng/ml. An appropriate amount of loading buffer was added to DNA 
sample. A 1 Kbp DNA marker and an appropriate amount of samples were loaded into 
each well. Electrophoresis was performed in 1X TAE with 100 V for the time required to 
obtain satisfactory separation, usually 40 mins. DNA was visualized under UV light on 
trans-illuminator and digitally photographed using G-box imaging instrument and GeneSys 
analysis software. 
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2.2.1.2.3 Agarose gel purification 
Using a clean scalpel, the approximate size DNA fragment was excised from the gel. The 
slice was weighed in a 1.5 ml eppendorf tube. Purification proceeded using the Qiagen
®
 gel 
extraction kit, in accordance with manufacturer’s instruction. 
2.2.1.2.4  Polymerase chain reaction (PCR) 
PCR was performed in a 0.2 ml tubes (Sarstedt) in Verity
®
 – in a 96 well thermal cycler 
(Applied Biosystems). The PCR mix was prepared containing the following: 
10X buffer for KOD hot start DNA polymerase, 1.5 mM of 25 MgSO4, 0.2 mM of each 
deoxyribonucleoside triphosphate (dATP, dCTP, dGTP, dTTP), 0.3 μM of each primer, 
0.02 U of KOD hot start polymerase; 10 ng of plasmid DNA and PCR grade water to make 
up final volume 50 μl.  
The following method was used on the thermal cycler: 
Reaction volume: 50ul  
Cover temperature: 105
◦
C  
Stage 1 temperature 95.0
◦
C; time (M:S): 2:00  
Stage 2 - for 20 cycles  
Step 1 temperature: 95.0
◦
C; time (M:S): 0:25  
Step 2 temperature: 66.7 (varies as per primer melting temperature); time(MM:SS): 0:55  
Step 3 temperature: 72.0; time (M:S): 1:00  
Stage 3 
Step 1 temperature: 70.0; time (M:S): 10: 
Step 2 temperature: 4.0; time: infinity  
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The success of amplification was assessed using agarose gel electrophoresis. 
2.2.1.2.5  Primer design 
Where possible, primers were selected using the following parameters: 
 Melting temperature between 57
◦
C and 63
◦
C 
 (G+C) content between 30-80%  
 Length between 18-22 bp 
 Less than 2
◦
C difference in melting temperature between the two primers.  
Wherever necessary, the parameters were relaxed to the following: 
 Length between 18-27 bp 
 Melting temperature 55
◦
C and 65 
◦
C  
Blast searches were performed to test the specificity of primer pair. 
2.2.1.2.6 Direct PCR purification 
PCR products (50 μl) were purified using the Qiagen® PCR purification kit in accordance 
with the manufacturers protocol.  
2.2.1.2.7 DNA quantification 
DNA was quantified by applying Beer-Lambert Law (A = ΕCL) relating absorbance to 
DNA concentration (C). Absorbance (A) readings was measured at 260 nm (L). The 
extinction co-efficient (E) used for double stranded DNA was 50. Absorbance readings 
were determined by NanoDrop
®
 spectrophotometer (NanoDrop technologies).  
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2.2.1.2.8 Ligation 
The ligation reaction contained 10X buffer (1 μl), 3X insert, 100 ng vector DNA, T4 DNA 
ligase (1μl) and molecular grade deionized water (D/W) to make up the final volume of 10 
μl. The reaction was mixed and incubated overnight at room temperature (~22
◦
C). 
2.2.1.2.9 Transformation 
Rubidium chloride competent origami B strain of E.coli cells were thawed for 2 mins on 
ice.  ligation product (5 μl) was inserted into an Eppendorf tube with a 50 μl aliquot of 
bacterial suspension, followed by 1 min on ice. Immediately after heat shock (42
◦
C for 90 
sec), 950 µl of LB-medium was added, followed by incubation with shaking at 200 rpm for 
1 hour. After incubation, 100 µl was plated on an agar plate containing ampicillin (100 
µg/ml), kanamycin (50 µg/ml), and tetracycline (15 µg/ml) and incubated at 37
◦
C 
overnight. 
2.2.1.2.10 Plasmid sequencing 
Plasmid sequencing was performed by MWG Eurofins Germany 
2.2.1.2.11 Computational analysis  
Blast: web based BLAST analysis was performed on Ensemble (Ensemble, 2016) 
Alignments of DNA sequence – DNA sequence were aligned using the program ClustalW2 
(Larkin et al. 2007) 
Expassy translate – DNA sequences were translated to protein sequence using Expassy 
translate tool (Expassy translate, 2016) 
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Expassy compute – the theoretical molecular weight (Mr) of proteins were computed by 
entering protein sequence into Expassy compute (Expassy compute, 2016) 
2.2.2 Protein expression 
 Origami B cells carrying the desired plasmid were picked and selected in 4 ml LB broth 
containing ampicillin (100 µg/ml), tetracycline (15 µg/ml) and kanamycin (50 µg/ml). 
Cells were grown overnight at 37
◦
C at 200 rpm. 1:1000 dilution of each starter culture was 
inoculated into LB broth containing ampicillin (100 µg/ml), tetracycline (15 µg/ml) and 
kanamycin (50 µg/ml) and grown until an Abs 600nm 0.6-0.7 at Abs 600 nm was reached. 
Following this step, temperature was reduced to 22
◦
C and 0.4 mM IPTG was added to the 
culture and grown at 200 rpm for 16 hours. 
2.2.3 Cell lysis 
Cultures were centrifuged at 12,000 x g for 30 mins at 4
◦
C. Supernatants were discarded 
and cell pellets allowed to air dry. The cell pellets were re-suspended thoroughly in lysis 
buffer (150 mM NaCl, 150 mM HEPES, 1 mM PMSF, 2mg/ml lysosome) and placed on a 
roller at 4
◦
C for 45 min. This solution was freezed/thawed-lysed in a -80
◦
C freezer for 1 
hour and thawed in a 20
◦
C water bath. The solution was then centrifuged at 47,900 x g in 
an ultracentrifuge for 45 min at 4
◦
C. An aliquot of the clarified supernatant was collected 
for analysis on SDS-PAGE and the remainder was purified by IMAC. 
2.2.4  Purification of recombinant proteins 
All recombinant proteins used in this study contained a hexa -histidine (his6) tag for 
affinity purification using immobilized metal chelate affinity chromatography (IMAC).  
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IMAC separates proteins or peptides, based on co-ordinate covalent interaction between 
immobilized metals ions such as nickel (Ni
+2
) or cobalt (Cu
+2
) and specific amino acids 
(such as histidine). Recombinant proteins are genetically modified to include protein tag 
such as glutathione-S-transferase (GST), hexa-histidine (his6) etc. The stationary phase 
consists of nickel or cobalt ions immobilized by co-ordinate covalent interaction with 
chelator. The hexa-histidine tags binds to immobilized nickel or cobalt ions, thereby, 
separating the non-selective proteins. The bound histidine tagged protein can be eluted by 
addition of imidazole, which displaces the histidine tagged protein.  
Ni-NTA resin (2 ml) was added to a commercial 20 ml column and washed with 
equilibration buffer (20 mM HEPES, 150 mM NaCl, pH 8.0). The clarified supernatant 
was mixed with equilibration buffer at 1:1 ratio and incubated with the resin for 1 hour at 
4
◦
C on a roller. Following binding, the mixture was placed back into the column and the 
flow through collected and stored on ice. The resin bound recombinant proteins were 
washed three times with wash buffer (equilibration buffer + 50 mM imidazole). Bound 
proteins were eluted at least three times with one bed volume (2ml) of elution buffer per 
fraction (20 mM HEPES, 150 mM NaCl, 500 mM imidazole). The eluted fractions were 
buffer exchanged into PBS using a PD-10 column, following the protocol provided by GE 
Healthcare. Concentrations of the eluates were determined by Bradford assay, as described 
in Section 2.2.4.4. Samples from each of the IMAC purification steps were separated by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) and protein was 
stained as described in Section 2.2.4.1 and 2.2.4.2, respectively. Purified and buffered 
exchanged fractions were stored at -20
◦
C.  
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2.2.4.1  SDS-PAGE  
This was used to separate proteins on the basis of size with SDS detergent being added to 
remove any secondary or tertiary structures. Proteins were loaded onto manually prepared  
acrylamide gels and run with 1 x electrophoresis buffer at 120 volts (stacking) and 170 
volts (resolving gel) until protein were separated according to their sizes, corresponding to 
the pre-stained protein marker. 
For Western blotting, protein gels were electrophoretically transferred to a Immobilon™ 
PVDF membrane for immunoblot assay as described in Section 2.2.4.3. 
2.2.4.2  Comassie blue staining 
Gels were prepared as per 2.2.4.1 and placed in heated 0.25% Coomassie brilliant blue G 
250 in 10% acetic and 45% methanol for 2-4 hours with gentle rocking to distribute the dye 
evenly over the gel. Gels were washed once with distilled H2O and placed in e-stain using 
30% methanol/10% acetic acid until protein bands became distinct. 
2.2.4.3 Western blotting  
A piece of PVDF membrane with a rated pore size of 0.45 μm (Millipore) was soaked for 
about 30 second in methanol followed by rinsing with deionized H2O, before soaking in 
transfer buffer. The sponge and filter paper were also soaked in transfer buffer for 15 mins 
and assembled as "sandwich" as follows: sponge, filter paper, PVDF membrane, protein 
gel, filter paper and sponge. This sandwich cassette was tightly sealed with the membrane 
side facing towards the positive electrode and gently placed in a transfer tank (TE62, 
Hoefer Inc.) filled with transferring buffer as above and transferred for 2-3 hours at 45 
volts at 4°C. The membrane was then blocked for 1 hour at room temperature in 5% bovine 
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serum albumin in tris-buffer saline tween-20 (0.1% Tween 20 in TBS). The membrane was 
incubated with primary antibody diluted in blocking buffer for 1 hour at room temperature 
or at 4
◦
C overnight. After washing 3 x 10 min with 0.1 % Tween-20 in TBS, membranes 
were incubated for 1 hour at room temperature with horseradish peroxidase conjugated 
anti-species secondary antibodies diluted in blocking buffer. The membranes were washed 
as described above; proteins were detected by ECL reagent which contains a luminol 
substrate of horseradish peroxidase and can be converted to a light releasing substance. 
Images were recorded using G BOX Chemi-16 gel documentation system and intensities 
quantified with Image J software. 
2.2.4.4 Protein concentration determination by BCA assay kit  
The BCA protein assay combines the well-known reduction of Cu2+
 
to Cu+ by protein in an 
alkaline medium with the highly sensitive and selective colorimetric detection of the 
cuprous cation (Cu+) by bicinchoninic acid (Thermo Fischer 2016). The first step is the 
chelation of copper by protein in an alkaline solution to form a blue colored complex. In 
this step, known as the biuret reaction, peptides containing three or more amino acid 
residues form a light blue colored chelate complex with cupric ions in an alkaline 
environment (pH 8.0). Proteins will react to produce a light blue to violet complex that 
absorbs light at 540 nm. The intensity of the color produced is proportional to the number 
of peptide bonds participating in the reaction. In the second step of the color development 
reaction, BCA, a highly sensitive and selective colorimetric detection reagent reacts with 
the cuprous cation (Cu+) that was formed in step 1. The purple-colored reaction product is 
formed by the chelation of two molecules of BCA with one cuprous ion. The BCA/copper 
complex is water-soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations (Thermo Fisher 2015).  
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Briefly, 25 μl of sample from each fraction or BSA standard were applied to a 96 
microplate; 200 μl mixture of reagent A and B (50:1) supplied in the kit were added to each 
well. The plate was mixed thoroughly and incubated for 30 minutes at 37°C before 
absorbance at 562 nm was read. Concentrations were calculated from the linear range of 
the standard curve.  
2.2.4.5 Statistical analysis  
Data were calculated and graphs generated by GraphPad Prism 4.0; each point represents 
the means ± S.E.M as indicated in figure legends of section 3.4 (Millar 2001). 
2.2.5 HEK 293 cell culture and maintenance  
LentiX-HEK 293 was used because of the ease of handling, their robust growth rate, low 
cost medium requirements and high capacity for recombinant protein expression. 
HEK293T contains the SV40 large antigen that amplifies transfected plasmid and 
expression of desired gene products. HEK 293T cells were grown at 37
◦
C , 5% CO2 in 
sterile T-25 or T-75 flat bottom flasks in complete Dulbecco’s modified Eagle’s medium 
(DMEM). Full DMEM consisted of 10% fetal bovine serum (FBS), 1% penicillin 
(100units/ml)/streptomycin (100 μg/ml), 1% Glutamax (0.4mM-L-glutamine). 
Cells were split every two-three days. During the passaging process, old medium was 
discarded. Cells were washed with sterile PBS (two times); 0.5% of trypsin was added and 
kept at 37
◦
C for up to 2 mins. Fresh full DMEM was added to cells and transferred into 
sterile 50 ml conical tubes and centrifuged for 1 min at 300 x g. The supernatant medium 
was discarded and replaced with fresh full DMEM. Cells were subjected to gentle and 
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continuous aspiration by using sterile 1ml pipette, to disrupt any lumps formed due to 
centrifugation. 
2.2.5.1 Transfection of HEK293 cells. 
For ease of transfection, cells were grown in 154 cm
2 
collagen coated petri-dishes. Freshly- 
passaged HEK 293T cells grown up to ~90% confluency were used for transfection. Prior 
to transfection, the medium from the plates to be transfected was replaced with full DMEM 
with lowered serum concentration (consisting of 2% of FBS instead of 10% FBS). Vector 
DNA (50µg) to be transfected was added to 5ml serum-free medium followed by addition 
of 75µl Polyethylenimine (PEI) stock (1 mg/ml) to make the DNA: PEI ratio 1:1.5. The 
solution was left at room temperature for 10 mins to allow formation of DNA-PEI. After 
10 mins, the DNA-PEI complex was added to the petri-dishes with brief rotation to allow 
mixing. After 8-12 hours the conditioned medium with PEI was discarded and replaced by 
fresh full DMEM with (2% serum) low serum. 48 hours later, the conditioned medium was 
collected for purification.  
2.2.6 PC-12 cell culture and maintenance 
PC-12 cells were provided by ATCC (CRL 1721). The cells were maintained using T-25 
and T-75 cm flasks in complete RPMI-16 medium at 37 °C under a humidified 5% CO2 
atmosphere. Complete RMPI-16 consist of 10% horse serum, 5% fetal calf serum, 100 
units/ml penicillin, and 100 μg/ml streptomycin. Cells were passaged every three days; 
stocks were stored in liquid nitrogen in a medium consisting of 10% DMSO and 90% 
complete RPMI-16 media (Greene and Tischler 1976; Levi et al. 1985).  
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2.2.6.1  ERK phosphorylation on PC-12 cells  
Cells (1x10
5
 per well) were plated on poly-L-lysine coated 12 well plates. Cells were 
maintained for 24 hours in complete RPM-16 medium. Cells were serum starved for 2 
hours prior to their treatment with control (7S NGF) or test samples for ERK 
phosphorylation. 
2.2.6.2 SNAP-25 on PC-12 cells 
Sterile 12-or 24-well plates were coated with collagen, and kept in the sterile environment 
of laminar air flow until they appear dry (this step was considered necessary to avoid 
minimum presence of acetic acid present in collagen). Cells (1x10
5 
per well) were plated 
on collagen coated well plates. Addition of 7S NGF (200 ng/ml) to PC-12 cells maintained 
in complete RPMI-16 medium, led to differentiation and neurite outgrowth of PC-12 cells. 
PC-12 cells were supplemented with 7S NGF for 7 days in complete RPMI -16 medium. 
Every two days, cells were replenished with fresh complete RPMI-16 medium. Cells were 
serum starved for 24 hours prior to their treatment with control or test samples for SNAP-
25 cleavage.  
2.2.7  SH-SY5Y cell culture and maintenance 
SH-SY5Y neuroblastoma cells were provided by Dr. Hans-Georg König (RCSI, Dublin). 
SH-SY5Y cells were maintained using T-25 and T-75 cm flasks in complete 1:1 mixture of 
DMEM and  Ham’s F12 (DME F12) at 37 °C under a humidified 5% CO2 atmosphere. 
Complete DME F12 medium consists of 10% fetal calf serum, 1% L-glutamine 100 
units/ml penicillin, and 100 μg/ml streptomycin. Cells were passaged every three days, and 
stocks stored in liquid nitrogen in a medium consisting 10% DMSO and 90% complete 
DME F12. 
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2.2.7.1 ERK phosphorylation on SH-SY5Y cells 
SH-SY5Y cells (1x10
5
 per well) were cultured on sterile 12 or 24 well plates and 
maintained for 24 hours in complete DME F12 medium. Cells were serum starved for 2 
hours prior to their treatment with control (7S NGF) or test samples for ERK 
phosphorylation.  
Following treatment of SH-SY5Y cells with test samples as described in section 3.4, the 
wells were washed once with PBS before addition of 100 μl of loading buffer (56 mM 
sodium dodecyl sulfate, 0.05 M Tris-HCl, pH 6.8, 1.6 mM Ultrapure EDTA, 6.25% 
glycerol, 0.0001% bromophenol blue). Samples were boiled for 1 min at 95°C and then run 
on 12% SDS–PAGE gels. Following separation, proteins were transferred onto Immobilin-
P polyvinylidene difluoride membranes, and then incubated for 30 min in blotting solution 
(5% BSA, Tris, buffered saline, (0.1%) Tween -20). The Rabbit Phospho p42/44 ERK and 
Rabbit p42/44 ERK primary antibodies were added at 1:1000 dilutions to the blotting 
solution and incubated for 18 h. Membranes were washed three times in Tris, buffered 
saline, Tween -20 for 10 min and then incubated for 30 min in the blotting solution 
containing secondary peroxidase-conjugated goat anti-rabbit antibodies, respectively. 
Membranes were washed three times in Tris, buffered saline, Tween -20 (0.1%) for 10 min 
Immunoreactive proteins were detected by ECL reagent which contains a luminol substrate 
of horseradish peroxidase and can be converted to a light releasing substance. Images were 
recorded using G BOX Chemi-16 gel documentation system and intensities quantified with 
Image J software. (Arsenault et al. 2010). 
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2.2.8 Cytochemical staining and microscopic recording of images  
Cover slips were surface sterilized with 96 % ethanol under the laminar air hood, and 
placed in sterile 12-or 24-well plates. Cover slips were coated with rat tail derived 
collagen. Cover slips coated plates were kept in the sterile environment of laminar air flow 
until they appeared dry. 
2.2.8.1  PC-12 cells 
PC-12 cells (1x10
5
) were cultured as described in Section 2.2.6. In order to detect SNAP-
25 by cytochemical staining, neurite outgrowth of PC-12 cells was considered necessary 
and achieved by supplementing complete RPMI -16 medium with 7S NGF (500 ng/ml) for 
seven days. Cells were replenished with fresh complete RPMI-16 medium containing 7S 
NGF after every two days. To detect TrkA receptors by cytochemical staining, PC-12 cells 
were cultured in full RPMI-16 medium for three days. 
Coverslips were washed three times with Dulbecco’s phosphate buffer saline (lacking 
Mg2+and Ca2+), then fixed for 20 minutes with 3.7% paraformaldehyde at room 
temperature in PBS. The cells were then washed with PBS three times, followed by 
permeabilization for 5 minutes with 0.2% Triton X-100 in PBS before blocking with 1% 
goat serum in PBS for 1 hour. Primary antibodies were applied in the same solution and 
left overnight at 4
º
C; after extensive washing, fluorescently-conjugated secondary 
antibodies were added for 1 hour at room temperature.  Counter-staining of nuclei was 
carried out with DAPI (1 μg/ml in water) added before the final wash. 
Immuno-fluorescent pictures were taken with an inverted confocal (Zeiss) or an Olympus 
IX71 microscope equipped with a CCD camera. Images were analyzed using Zeiss 
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confocal software and Image-Pro Plus 5.1, respectively. The omission of primary antibody 
from the fluorescence staining gave the background for secondary antibody; the signal 
intensity above this was taken as positive reactivity.  
2.2.8.2 SH-SY5Y cells 
SH-SY5Y cells (1x10
5
) were cultured as described in Section 2.2.7.SH-SY5Y cells were 
cultured in complete DM F12 medium. Every two days, cells were replenished with fresh 
complete DM F12 medium. Immuno-cytochemical staining steps of SH-SY5Y cells were 
same as described for PC-12 cells in Section 2.2.8.1. 
2.2.9 Hemocytometer counting 
A glass hemocytometer and coverslip were cleaned with alcohol before use. Coverslip was 
affixed to the hemocytometer. The presence of Newton's refraction rings under the 
coverslip indicated proper adhesion. Cells were mixed well prior to aspirating 20 µl into an 
Eppendorf tube. Trypan blue (0.4%) 20 µl mixed with the 20 µl of cells (1:1 ratio of cells: 
trypan blue). In some cases, 1:2 ratio of cells: trypan blue was achieved by aspirating 20 µl 
trypan blue treated cells into another Eppendorf with 20 µl of trypan blue. Trypan blue-
treated cell suspensions (20 µl) were applied very gently to both chambers underneath the 
coverslip of the hemocytometer, allowing the cell suspension to be drawn out by capillary 
action. Using a microscope, the grid lines of the hemocytometer were focused with a 10X 
objective. Using a hand tally counter, live unstained cells that do not take up trypan blue 
stain were counted in one set of 16 squares. A counting system was used, whereby cells 
were only counted when they were set within a square and were on the right-hand or 
bottom boundary line. Similarly, 4 sets of 16 corners were counted. 
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Formulae to determine number of cells per millimeter = counted number of cells X 
(dilution factor) X (10
4
) / 4 (squares) 
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3 Molecular engineering of proteins for targeting SNARE-cleaving 
protease into neuroendocrine cells
This following section describes recombinant fusion proteins LC.HN.HCN/A.βNGF 
(abbreviated as /A∆HCCN), Vamp2.EGF and Vamp2.βNGF expressed in E.coli cells. This 
work was performed in conjunction with Dr. Matthew King.  
 Construct for BoNT/A-based chimera /A∆HCCN  3.1
In order to determine if the BoNT/A endopeptidase could be delivered into neuroendocrine 
cells via a non-native binding receptor (tropomyosin receptor kinase A - TrkA), Dr 
Matthew King designed chimera LC.HN.HCN/A.βNGF (/A∆HCCN). It consists of the 
LC.HN.HCN/A domain from BoNT/A fused to a cDNA encoding the βform of human NGF 
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(Ullrich et al. 1983). Structural elements of BoNT/A, chimera /A∆HCC and chimera 
/A∆HCCN are shown in Fig. 11. 
 
Fig. 11 Schematic 
representation showing 
structural domains of 
BoNT/A, chimera 
/A∆HCC and chimera 
/A∆HCCN. (A) BoNT/A consists of light chain (LC), translocation (HN), N- terminal (HCN) and 
C-terminal (HCC) binding domains. (B) /A∆HCC comprises BoNT/A without the binding sub-
domain HCC. (C) Chimera /A∆HCCN is comprised of gene fragments LC, HN and HCN from 
BoNT/A fused to the βNGF gene. The nucleotide sequence encoding a linker 
(GGGGSGGGGS) is indicated with ( ). 
3.1.1 Generated chimera /A∆HCCN: cloning and expression  
The binding domain (HCC) of BoNT/A is reported to bind synaptic vesicle protein (SV2) 
and gangliosides of motor neurons. The approach used in this study involved replacing the 
binding domain (HCC) with βNGF which was hoped would bind and target the LC/A to 
sensory neurons, rather than motor neurons. This study focused on creating a conjugate of 
βNGF with BoNT/A∆HCC (/A∆HCC) using recombinant DNA technology to seek a cost-
effective method for large scale production of such proteins. 
In this study Dr Matthew King created pET32b.chimera/A∆HCC and I carried out the 
expression and IMAC purification of the encoded protein. Dr Matthew King conjugated 
chimera /A∆HCC with preceding sequences encoding thioredoxin (Trx), an S-tag and his(6) 
tag of the vector pET32b (Appendix 1). The resultant DNA encoded the Trx.his(6).S-tag. 
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LC.HN.HCN.βNGF protein, abbreviated as Trx./A∆HCC. The details of this protein will be 
elaborated later in this section. Chimera Trx./A∆HCC.N was present within SacI and XhoI 
sites of vector pET32b (Fig. 12A).  
 
Fig. 12 Design and cloning of 
chimeric construct 
pET32b_/A∆HCCN. (A)pET32b-
Chimera /A∆HCCN encodes a single 
chain protein (abbreviated Trx. 
/A∆HCCN) consisting of thioredoxin 
(Trx)tag (black), S tag known as 
solubility tag (orange), His (6) tag 
(green), LC.HN.HCN /A(red) fused to 
βNGF (yellow) by a flexible linker 
(brown). The molecular weight (Mw) 
of Trx. /A∆HCCN is 158 k, predicted 
by its nucleotide sequence using an 
Expasy compute tool. (B) Image 
depicts ethidium bromide stained agarose gel consisting of a DNA Ladder (L) and linearized DNA 
of pET32b-Chimera /A∆HCCN after a single cut with NCO I restriction endonuclease for 1 hour at 
37
◦
C. Due to the presence of one NCO I restriction endonuclease site within the vector pET32b 
/A∆HCCN, cleavage at this locus gives a band at size 9.5 kbp indicating linearized DNA. 
Chimeric construct pET32b/A∆HCCN was transformed into the origami B strain of E.coli, 
using the heat shock technique (see section 2.2.1.2.9), and the cells were cultured in Luria-
Bertani medium (see section 2.2.2). This strain of E.coli was used as it is K-12 derivative 
that has mutations in both the thioredoxin reductase (trxB) and glutathione reductase (gor) 
genes, which enhance the formation in the cytoplasm of the six disulphide bonds of the 
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βNGF homodimer. Trx is also commonly employed as a fusion tag to avoid incorporation 
into inclusion bodies, by taking advantage of its intrinsic oxido-reductase activity 
responsible for the reduction of disulfide bonds through thio-disulfide exchange (Prinz et 
al.1997; Aslund et al. 1999 and LaVallie et al. 2000). Thus, it was envisioned that the 
thioredoxin tag might facilitate oxidative refolding of Trx./A∆HCCN in the periplasmic 
environment of E.coli. S-tag is a 15 amino acid oligopeptide (Lys-Glu-Thr-Ala-Ala-Ala-
Lys-Phe-Glu-Arg-Gln-His-Met-Asp-Ser) derived from pancreatic ribonuclease A. The 
abundance of its charged and polar residues makes it an extremely soluble structured 
peptide with a net charge near neutral pH that could facilitate expression of soluble Trx. 
/A∆HCCN (Raines et al. 2000). In this study expression of chimera /A∆HCCN was not tried 
without the Trx and S-tag. The his(6) tag consists of six consecutive histidine residues that 
coordinate, via the histidine imidazole rings, transition metal ions such as Ni
+2
 or Co
+2
 
immobilized on beads or a resin for purification using immobilised metal chelate affinity 
chromatography (IMAC). Carboxymethylasparte agarose resin (Talon
®
, from ClonTech) 
has a high binding capacity, and was used for purification of Trx./A∆HCCN from crude cell 
lysates. The advantages of using his(6) tag include: (a) its small size and charge minimises 
interference with Trx./A∆HCCN structure and function (b) Trx./A∆HCCN can be eluted 
under mild conditions by imidazole competition (Costa et al. 2014, Terpe, 2003;Kimple 
and Sondek, 2004; Li, 2010). Two thrombin cleavage sites, indicated by blue arrows (Fig. 
13A), were inserted to allow removal of the his(6) tag and to convert the single polypeptide 
into disulphide-bridged dichains (Fig.13A).  
Three antibiotics namely ampicillin (100 µg mL 
-1
), tetracycline (12.5 µg mL 
-1
) and 
kanamycin (50 µg mL 
-1
) were used for selection. The origami B strain of E.coli consists of 
a gene for tetracycline resistance in its chromosome and is, therefore, able to degrade 
tetracycline present in the Luria-Bertani medium. The presence of kanamycin maintains a 
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transgene trx B in origami B cells which, in turn, may facilitate formation of six disulphide 
bonds in βNGF homodimer within the cytoplasm (Prinz et al. 1997 and LaVallie et al. 
1993). The gene for ampicillin resistance is present on the pET32b vector; therefore, 
ampicillin facilitates selection of cells transformed with chimeric construct pET32b 
/A∆HCCN.  
To trigger transcription from the lac operon (Lac I) and the expression of the protein 
Trx./A∆HCCN, 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the 
medium used  for the cultivation of the E.coli  cells. The lac operon is required for the 
transport and metabolism of lactose, as a carbon source when glucose is not available. Lac 
I is a functional unit of E.coli genomic DNA consisting of three structural genes lac Z, lac 
Y and lac A, a promoter, a terminator and an operator. The gene product of lac Z is β-
galactosidase (an enzyme that cleaves lactose to glucose and galactose). Lac Y encodes 
lactose permease, a protein that facilitates transport of lactose into the cell. Lac A encodes 
an enzyme galactoside O acetyltransferase that transfers an acetyl group from acetyl-CoA 
to β-galactosides. IPTG is a molecular mimic of allolactose, a lactose metabolite that does 
not get hydrolysed by β-galactosidase, but does trigger transcription from the lac operon. 
IPTG binds to the lac repressor (a region of DNA which inhibits transcription of lac Z, lac 
Y and lac A genes) and releases the tetrameric repressor from the lac operator in an 
allosteric manner, thereby allowing transcription of genes lac Z, lac Y and lac A. The 
sulphur atom of IPTG forms a chemical bond, which is non-hydrolysable by the cell and, 
thereby, prevents IPTG degradation. IPTG uptake at low concentrations involves lactose 
permease but at higher levels it enters cells independent of lactose permease (Malan et 
al.1984; Hansen et al.1998 and Marbach and Bettenbroch 2012).  
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3.1.2 IMAC purification followed by thrombin nicking yielded protein 
Trx/A∆HCCN 
IMAC yielded 1.2 mg of protein per litre of culture. Bands registered at molecular weight 
(Mr) 158 (Fig. 13A) by Coomassie staining on 10% SDS-PAGE suggest the presence of 
Trx/A∆HCCN but as a minor fraction (Fig. 13B).  
Incubation with thrombin achieved nicking of the chimera /A∆HCCN, as demonstrated by 
the loss of the 144 k band and the appearance of bands at Mr ~90 k for HN.HCN.βNGF and 
molecular weight ~54 k for LC/A fused to S tag upon SDS-PAGE in the presence of 2-
mercaptoethanol. A band appeared at Mr ~144 k, in the absence of reducing agent 
indicating that the inter-chain di-sulphide bond had been formed (Fig. 13C).  
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Fig.13 Expressed chimera A/HCC∆NGF. (A) Depicts the predicted modular structure and 
molecular weight (Mr) of protein Trx./A∆HCCN determined by using Expasy compute tool, which 
uses a coded algorithm to predict the iso-electric focusing point and molecular weight of proteins 
based on their amino acid sequences. Treatment of protein Trx. /A∆HCCN with thrombin (200 μg of 
protein and 2 μg of enzyme in 0.2 ml 50 mM HEPES/50 mM NaCl, pH 7.4 for 1 hour at 37
◦
C for 40 
minutes) resulted in nicking of thioredoxin tag and formation of /A∆HCCN dichain (ICNT unpublished 
data). The latter consists of two moieties namely, LC/A fused S tag and HN.HCN/A.βNGF. The 
dichain was inter-linked under non-reducing conditions due to presence of interchain disulphide 
bond formation. In the presence of reducing agent such as 2-mercaptoethanol, reduction of sulphur 
atoms involved in the disulphide bond formation led to separation of inter-linked dichains. The Mr of 
LC/A fused S tag and HN.HCN/A.βNGF were 54 k and 90 k, respectively. (B) Coomassie stained 
10% SDS PAGE gel of Total lysate (total), soluble bacteria lysate (Sol) and various fractions 
obtained during IMAC purification of Trx./A∆HCCN; FT1-FT2 - flow through (non-binding), W – 
wash, E1-E4 – eluate fractions, dSE – E1-E4 pooled and desalted by gel filtration. All samples 
excluding wash (w) and one imidazole eluate (E3) indicate the presence of a band at 158 Mr 
(labelled *), which is the predicted size of Trx. /A∆HCCN. (C) Coomassie stained protein gel of Trx. 
/A∆HCCN under non-reducing conditions after thrombin treatment Bands were detected at the 
molecular weight 144 k. (D) Coomassie stained protein gel of Trx. /A∆HCCN under reducing 
conditions after thrombin treatment. Bands were detected at the molecular weights 90 k and 54 k 
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corresponding to those predicted in Fig. 13A. A number of other bands visible in (C) and (D) may 
be due to contaminants from E.coli or degraded recombinant protein. 
3.1.3  Characterization of generated protein /A∆HCCN in neuroendocrine 
cells 
The reason for designing chimera /A∆HCCN was to ascertain whether its encoded protein 
LC.HN.HCN/A.βNGF can enter neuroendocrine cells via receptor TrkA, by determining 
SNAP-25 cleavage due to delivered LC/A protease activity. SH-SY5Y cells and PC-12 
cells are derived from human neuroblastoma and rat adrenal medulla, respectively. They 
are accepted as models to evaluate the potency of BoNT/therapeutics due to several 
advantages like: ease of culture, generated in large quantities and sensitivity to both NGF 
and BoNT/A. 
3.1.3.1 PC-12 cells and SH-SY5Y cells contain TrkA and SNAP-25 and, thus, could 
be used to assess receptor binding and uptake of chimera /A∆HCCN 
The presence of TrkA in SH-SY5Y cells and PC-12 cells was demonstrated by immuno-
fluorescent microscopy and counter staining with DAPI (Fig. 14/A,B and 15/A,B).  
Before assessing whether chimera /A∆HCCN can enter neuroendocrine cells (such as PC-12 
cells and SH-SY5Y cells) and if its LC/A protease cleaves SNAP 25, it was important to 
demonstrate the presence of SNAP-25. Using a specific antibody against SNAP-25 and 
counter staining using DAPI, both cells showed labelling of SNAP-25 in cell bodies and 
neuron like process (Fig. 14/C,D and 15/C,D).  
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Fig. 14 Visualisation of TrkA receptor and SNAP-25 on PC-12 cells. PC-12 were 
cultured in vitro on coverslips without 7S NGF as described in Chapter 2. Cells were fixed and 
permeabilised. (A) The PC-12 cells were stained with rabbit anti-TrkA (1:5000) overnight at 4
◦
C, 
washed with phosphate buffer saline followed by goat anti rabbit Alexa Fluor 568 (1:1500). For (B) 
the PC-12 cells were exposed only to goat anti-rabbit Alexa Fluor 568 (1:1500). In (C) and (D), PC-
12 cells were differentiated with 500 ng per ml of 7S NGF in order to visualize SNAP-25 along the 
differentiated neurites, as described in Chapter 2. Seven days post culture, cells were fixed and 
permeabilised. The cells were stained with mouse anti-SNAP-25 (1:5000), washed with phosphate 
buffer saline followed by goat anti-mouse Alexa Fluor 488 (1:1500). In the case of (D), the PC-12 
cells were treated identically except that mouse anti-SNAP-25 (1:5000) was omitted. Samples (A) 
and (C) were counter-stained by DAPI. All the samples were mounted onto slides and viewed in an 
inverted microscope under fluorescent mode.  
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Fig. 15 Microscopic demonstration of the presence of TrkA receptors and SNAP-25 
in SH-SY5Y cells. SH-SY5Y cells were grown on cover slips as described in Chapter 2. (A) The 
SH-SY5Y cells were stained with rabbit anti-TrkA (1:5000) overnight at 4
◦
C, washed with phosphate 
buffer saline followed by goat anti rabbit Alexa Fluor 568 (1:1500). For (B) the SH-SY5Y cells were 
exposed only to goat anti-rabbit Alexa Fluor 568 (1:1500). In (C) and (D), the SH-SY5Y cells were 
stained with mouse anti-SNAP-25 (1:5000), washed with phosphate buffer saline followed by goat 
anti-mouse Alexa Fluor 488 (1:1500). In the case of (D), the SH-SY5Y cells were treated identically 
except that mouse anti-SNAP-25 (1:5000) was omitted. Samples (A) and (C) were counter-stained 
by DAPI. All the samples were mounted onto slides and viewed in an inverted microscope under 
fluorescent mode. 
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3.1.3.2 Protein /A∆HCCN proved biologically inactive, as measured by antibodies to 
phospho-MAPK 42/44  
NGF preferentially binds to receptor TrkA (Huang and Reichardt 2003) which consists of 
an extracellular, an intracellular domain, a transmembrane, an intracellular juxta-membrane 
domains followed by tyrosine kinase domain and C-terminal tail (Weismann and de Vos 
2001). NGF stimulates TrkA receptor auto-phosphorylation at C-terminal tail at tyrosine 
490 which causes dimerization of the receptor via a cascade of signalling proteins Ras, C-
Raf and MEK, activated TrkA leads to phosphorylation of MAPK at sites Thr202 and 
Tyr204 (Segal, 2003; Cowley et al.1994)(Fig. 16A).  
In order to discover if the chimeric /A∆HCCN protein entered PC-12 cells, escaped the 
acidic compartments and cleaved SNAP-25, PC-12 cells were grown in presence of 7S 
NGF for seven days as described in Section 2.2.6.2 of Chapter 2 (Fig. 16B). LC/A domain 
of BoNT/A (control) is expected at Mr ~ 50 k. Because of the contribution of the S-tag, the 
LC/A of chimeric /A∆HCCN protein is predicted at ~ 54 k (Fig. 12A); bands detected by 
antibody to LC/A at ~54 k indicated its presence. After exposure to 30 nM and 10 nM, 
/A∆HCCN protein separated from the translocation domain. Western blotting with specific 
mouse anti – SNAP -25 antibody confirmed the presence of intact and cleaved SNAP-25 in 
PC-12 cells. Treatment of PC-12 cells with Trx./A∆HCCN at concentrations of 30 nM and 
10 nM, but not at 3 nM, showed faint bands of cleaved SNAP-25 detected by specific anti-
SNAP-25 antibody, indicating that it is low in activity compared to control BoNT/A 
protease activity. The latter, in turn, could be due to 1) presence of S tag at the N-terminus 
of protein /A∆HCCN, suggested to reduce toxicity of its LC/A (Chen and Barbieri 2011) 
and 2) due to impurities in the protein /A∆HCCN. An additional explanation for the faint 
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bands could be due to non-specific binding and membrane uptake of /A∆HCCN protein by 
PC-12 cells.  
To confirm whether chimeric /A∆HCCN protein interacts with cell surface TrkA receptors, 
PC-12 cells were incubated with /A∆HCCN or control 7S NGF. Western blotting with 
rabbit anti-phospho MAPK 42/44 antibody showed that the specific control (7S NGF) led 
to phosphorylation of mitogen activate protein kinase (Mr = 42 k and 44 k), presumably at 
amino acid sites Thr202 and Tyr204 (Fig. 16C). However, chimeric /A∆HCCN protein did 
not show a detectable increase in phosphorylation of MAPK relative to that in non-treated 
control cells, indicating failure of receptor TrkA activation at cell surface of PC-12 cells. 
Thus, replacing the binding domain of BoNT/A (HCC) with βNGF (Fig. 11C) led to 
expression of chimeric protein LC.HN.HCN/A.βNGF, which proved to be biologically 
inactive. Reasons for this will be discussed in the General Discussion (Chapter 4). 
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Fig. 16 Chimera /A∆HCCN proved to be biological inactive on PC-12 cells. (A) On 
binding to TrkA, NGF activates an intracellular cascade of signaling proteins, including Ras, c-Raf 
and MEK.  This eventually leads to phosphorylation of MAPK 1/2 proteins at sites (circled red) 
Thr202/Tyr204. (B) Serum-starved PC-12 cells were treated with chimeric /A∆HCCN protein at 
different concentrations (30, 10 and 3 nM) and, for comparison, 10 nM of BoNT/A were treated with 
PC-12 cells. Western blotting by specific anti-SNAP-25 antibody detected bands at Mr 25 k and Mr 
~23 k indicating the presence of intact SNAP-25 and cleaved SNAP-25, respectively. As detailed in 
chapter 4, the higher bands detected by specific antibody to LC/A antibody at ~ Mr 54 k and Mr ~50 
k indicate the presence of LC/A fused S tag and LC/A of BoNT/A, respectively. The lower set of 
bands in all lanes show non-specific proteins detected by antibody to LC/A in PC-12 cells. (C) 7S 
NGF induced robust phosphorylation of ERK 1/2 (MAPK) compared to negative control (-). 
LC.HN.HCN./A.βNGF (represented as /A∆HCCN) failed to induce ERK 1/2 /MAPK phosphorylation. 
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  Protein stapling technology  3.2
Targeting the protease of BoNT/A to neuroendocrine cells by direct recombinant fusion of 
proteins, has several disadvantages such as, the unidirectional nature of protein translation 
(N–C), misfolding of protein, proteolytic degradation and low yields (Ferrari et al 2012; 
Arsenault et al 2013).  
During neuronal exocytosis, synaptic vesicles bind to SNAREs to form a tight tetra-helical 
complex. Arsenault et al. (2013) suggested exploiting the established selective and high-
affinity interaction of the α-helices from neuronal SNAREs to achieve biochemical 
coupling; this strategy has been termed protein stapling (Fig. 17). Protein stapling 
technology exploits the self-assembling property of three helical SNAREs such as SNAP-
25, synaptobrevin (also termed Vamp) and syntaxin-1 to form such tetra helical complexes 
(Fig. 17). Of the four helices in the tetra helical complex, SNAP-25 contributes two, 
syntaxin-1 contributes one and the Vamp contributes the final component (Sutton et al 
1998). The four α-helices spontaneously interact when mixed to form a tetra-helical tight 
interaction (Darrios et al. 2010). The assembled neuronal SNARE complex is stable at 
elevated temperatures and exhibits resistance to: chaotropic agents, strong detergents and 
proteases detailed in section 1.3.3.2 of this study (Sutton 1998, Sudhof and Rothman 
2009). 
 Using this approach, Arsenault et al. (2013) described the delivery of type A botulinum 
protease into neuroendocrine cells, using EGF. Arsenault et al. (2013) created individual 
components Vamp2 (25-84) fused EGF and SNAP-25 (22-206) fused LC.HN/A in E.coli 
via DNA recombination.  They were stapled together into a functional unit by addition of a 
synthetic peptide corresponding in sequence to residues (1-45) of syntaxin-1.  
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Fig. 17 Schematic representation of protein stapling. (A) Stapling reaction using 
LCHN/A-SNAP-25 (the protease domain, brown; the translocation domain, red, and a 
SNAP-25 (22-206) linker, green), the Vamp2 (25-84) linked to targeting receptor-binding 
ligand (yellow) and the syntaxin-1 peptide (1-45) (blue). Addition of the syntaxin-1 peptide 
(1-45) results in formation of an LC.HN/A.SNAP-25.syntaxin-1.Vamp2-targeting ligand. (B) 
shows targeting of the receptor-binding ligand EGF and βNGF monomer (yellow arrow) 
linked to Vamp2. Image adapted from Arsenault et al. 2013. 
In view of the lack of success in the generating biological-active /A∆HCCN fusion protein, 
it was decided to explore the potential of this stapling technology, as described by 
Arsenault et al. (2013) and in Chapter 1. In this section, the successful creation Vamp2 
fused to EGF in E.coli is described, which involved 1) the creation of chimeric construct 
encoding Vamp2 (25-84) fused to EGF and 2) generation of a chimeric construct encoding 
Vamp2 (25-84) fused to NGF. The study described in Arsenault et al (2013) used Vamp2 
fused EGF as the ligand to retarget the SNARE cleaving protease into sensory neurons 
whereas my study used NGF as the ligand to re-target the SNARE cleaving protease into 
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neuroendocrine cells. The difference between chimeric construct Trx.Vamp2.EGF and 
Trx.Vamp2.βNGF involved the replacement of gene encoding EGF with that encoding 
βNGF.  
3.2.1 Generation of a chimeric construct encoding Vamp2 (25-84) fused 
to EGF (Vamp2.EGF) in E.coli  
Dr Matthew King performed the cloning of Chimeric construct Trx.Vamp2.EGF and I 
expressed it in E.coli cells and purified it using IMAC.  
Chimeric construct Trx.Vamp2.EGF was transformed into the origami B strain of E.coli, 
using the heat shock technique; the cells were cultured in Luria –Bertani medium. DNA of 
chimeric construct Trx.Vamp2.EGF (Fig. 18A) encodes Trx (see above), his(6) tag, a 
thrombin cleavage site to allow removal of the his(6) tag, Vamp2 (amino acid 25-84) for 
SNARE stapling, 10 amino acid (GGGGSGGGGS) flexible linker and EGF. Ampicillin 
(100 µg mL
-1
), tetracycline (12.5 µg mL
-1
) and kanamycin (50 µg mL
-1
) were used as 
before. To trigger transcription of the lac operon (Lac I), expression of chimera 
Trx.Vamp2.EGF was induced by addition of 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) to the E.coli culture. During IMAC purification the total 
bacterial lysate was mixed with Talon
®
 resin at 4
◦
C for 1 hour before separating unbound 
proteins from the resin on gravity flow columns. After washing with wash buffer (150 mM 
NaCl, 20 mM HEPES and 10 mM imidazole), his(6) tagged proteins were eluted by 500 
mM imidazole; eluted proteins were separated from imidazole salt and buffer exchanged 
into storage buffer (20 mM HEPES, 145 mM NaCl pH 7.4) by gel filtration columns. 
Expression of Trx.Vamp2.EGF in the origami strain of E.coli followed by IMAC 
purification yielded 1.5 mg of total protein per litre, of which Trx.Vamp2.EGF formed 
~80% of total protein (Fig. 18/B,C). Thrombin treatment of IMAC purified 
  Chapter 3 
78 
   
Trx.Vamp2.EGF protein for 1 hour at 20
◦
C nicked Trx.his(6) tag. Incubation of thrombin 
treated Trx.Vamp2.EGF protein with Talon
®
 resin, followed by collection of unbound flow 
through using gravity flow columns, separated Vamp2.EGF and Trx.his(6) tag (Fig. 
19A).Western blotting with specific antibody to Vamp 1, 2, 3 showed thrombin cleavage 
separated Vamp2.EGF from the thioredoxin tag (Fig. 19B). 
Fig. 18 Expression and 
purification of chimera 
Trx.Vamp2.EGF (A) Schematic of 
chimera pET32B.Trx.Vamp2.EGF (B) 
Comassie staining of 15% SDS PAGE gel 
of bacteria soluble lysate and various 
fractions obtained during IMAC purification; 
FT - flow through (non-binding), W1 – 
wash, E1-E4 – eluate fractions, dSE – E1-
E4 pooled and desalted by gel filtration. 
Prominent bands were displayed at ~ Mr 29 k, which is the predicted molecular weight of 
Trx.Vamp2.EGF indicating its presence. (C) Western blot using antibodies against Vamp 1, 2, 3 of 
samples as described in B. Total lysate (Total) was mixed with Talon
®
 resin at 4
◦
C for 1 hour before 
separating unbound proteins (FT) from the resin on gravity flow columns. After washing with wash 
buffer (150 mM NaCl, 20 mM HEPES and 10 mM imidazole pH 7.4), his(6) tagged proteins were 
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eluted with 500 mM imidazole; eluted proteins were separated from imidazole salt and buffer 
exchanged (dSE) into storage buffer (20 mM HEPES, 145 mM NaCl pH 7.4) by gel filtration 
columns. Strong band at Mr 29 k confirms the presence of Trx.Vamp2.EGF. 
 
Fig. 19 Thrombin nicking of chimera Trx.Vamp2.EGF (A) Coomassie staining of thrombin-
treated Trx.Vamp2.EGF followed by IMAC purification on 15 % SDS-PAGE gel. At ~Mr 14 k, strong 
bands occur indicating the presence of Vamp2.EGF; slightly below, another band at Mr ~15 k, 
which is expected size of thioredoxin protein was detected indicating its cleavage following 
thrombin treatment of Trx.Vamp2.EGF. Occurrence of thioredoxin band (upper band) below the 
predicted Vamp2.EGF suggests that most of Vamp2.EGF protein was purified using IMAC 
purification. (B)  Depicts the Western blot of Trx.Vamp2.EGF after thrombin treatment followed by 
IMAC purification. A band detected by antibody to Vamp 1, 2, 3 at Mr of 14 k, confirming the 
presence Vamp2.EGF upon removal of thioredoxin protein after thrombin treatment. Stripped resin 
in Fig. 19 (A), (B) represents the recombinant protein solubilized from the Talon
®
 resin by SDS-
PAGE. 
A 
B 
A 
B 
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3.2.2 The creation of a chimeric construct encoding Vamp fused to NGF 
(Vamp2.βNGF) in E.coli  
Using the construct Trx. pET32b.Vamp2.βNGF created by Dr Matthew King (unpublished 
data generated as part of his work at ICNT during the course of this study), the work of 
Arsenault et al. (2013) was adapted as described in Section 3.2 to generate a fusion protein 
of Vamp2.βNGF in E.coli.  
Chimeric construct Trx.Vamp2.βNGF (Fig. 20) was transformed into the origami B strain 
of E.coli, using the heat shock technique; the cells were cultured in Luria –Bertani 
medium. Expression of chimeric protein Trx.Vamp2.βNGF in the origami strain of E.coli 
cells was followed by IMAC purification as described previously for other fusion proteins. 
Coomassie staining of SDS-PAGE (Fig. 21A) and Western blot (Fig. 21B) using antibody 
to Vamp 1, 2, 3 showed the majority of Trx.Vamp2.βNGF was insoluble. This suggested 
its presence in inclusion bodies due to the intracellular accumulation of aggregated 
Trx.Vamp2.βNGF protein. Attempts were made to separate inclusion bodies and isolate the 
Trx.Vamp2.βNGF from inclusion bodies as described by Rattenhol et al. 2001; however, 
during the dialysis step the protein aggregated.  
Lessmann et al. 2003 suggests that the Pre-Pro domain plays an important role in proper 
folding and intracellular sorting of mature βNGF. Lack of precursor Pro domain in the 
designed chimera Trx.Vamp2.βNGF and absence of components necessary for post 
translational processing of ProNGF into soluble mature βNGF homodimer in E.coli may 
have led to the formation of protein aggregates and incorporation into inclusion bodies.  
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Fig. 20 Generation of chimera pET32B.Trx.Vamp2.βNGF   Schematic of chimera 
pET32B.Trx.Vamp2.βNGF  
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Fig 21 Expression and purification of Vamp2.βNGF in the inclusion bodies of E.coli. 
(A) Coomassie staining of a 15% SDS PAGE gel of various fractions obtained during IMAC 
purification of Trx.Vamp2.βNGF protein as described in Fig. 18B. A strong band at the predicted 
molecular weight of approximately 35 Mr in (Total) indicates the presence of Trx.Vamp2.βNGF in 
the inclusion bodies. (B) Western blot on IMAC purified samples of Trx.Vamp2.βNGF on 10% SDS-
PAGE. Although anti Vamp 1,2,3 immunoreactivity was clearly evident in lysed bacteria, only a 
minor amount was found in the soluble fraction.  
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  Molecular engineering of proteins in mammalian cells for the 3.3
targeted delivery of SNARE-cleaving protease into neuroendocrine 
cells. 
To overcome the lack of success with expressing soluble βNGF fused to Vamp2 in E.coli 
cells, it was decided to explore a mammalian expression system. The study described in 
Colangelo et al.(2005) showed that active NGF could be expressed with good yield in 
mammalian cells. In the rough endoplasmic reticulum, naturally occurring NGF is 
synthesized as Pre-Pro precursor proteins. The precursor Pre-Pro signal of NGF plays an 
important role in post-translation modification and processing of biological-active 
homodimer, βNGF. The Pre (signal) peptides are removed by proteolytic processing in the 
lumen of the endoplasmic reticulum to yield stable Pro.NGF. Biophysical analysis reported 
by Lessmann et al. (2004) suggests that the Pro domain serves an important role in proper 
folding and intracellular sorting of mature βNGF. ProNGF is glycosylated at amino acid 
residues 61 and 121. Trimming of its N-linked oligosaccharide regulates the transport of 
Pro-NGF from endoplasmic reticulum to the trans-Golgi network, via clathrin-coated 
transport vesicles (Sutter et al. 1991). The Pro.βNGF is rapidly cleaved intracellularly at a 
four residue site (Arg-X, Lys/Arg-Arg) by furin (a protease of the prohormone convertase 
family) (Seidah et al. 1996). Furin (ubiquitously present in mammalian cells such as HEK 
293T cells) converts Pro.βNGF to a mature βNGF form (Li et al. 2010).  
 It was decided that this could be applied with some adaptations, together with the protein 
stapling technology to generate a soluble and biologically-active Vamp2.βNGF. The stages 
involved were: 1) the transfection and characterization of a chimeric construct 
pCDNA3.1ProβNGF encoding ProβNGF in HEK 293T cells and 2) generation of chimeric 
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constructs pCDNA3.1.Pro.Vamp2.βNGF and pCDNA3.1.Pro.βNGF.Vamp2 3) and 
characterization of these chimeras in human neuroblastoma SH-SY5Y cells to ascertain 
biological activity. As stated earlier, HEK 293T cell line is a derivative of human 
embryonic kidney 293T cells, which contains the Simian Vacuolating Virus 40 TAg (SV40 
T-antigen). SV40 T antigen is a hexameric protein that is a dominant-acting oncoprotein 
derived from the polyomavirus SV40 that allows for episomal replication of plasmid 
pCDNA3.1 containing the SV40 origin of replication. The function of T-antigen is 
controlled by phosphorylation, which attenuates the binding to the SV40 origin. Protein-
protein interactions between T-antigen and DNA polymerase-alpha directly stimulate the 
SV40 origin of replication. This allows amplification of transfected pCDNA3.1 and 
extended temporal expression of the transgene.  
In this case Pro.βNGF HEK 293 T cells were used as they were straightforward to grow 
and to transfect. Advantageously, these cells can be grown in low serum concentrations 
(2% fetal bovine serum), which facilitates efficient transfection using PEI. A more detailed 
description of transfection of HEK 293T cells can be found in Chapter 2. 
pCDNA3.1 is a plasmid widely used for high level stable or transient expression of 
transgenes in mammalian cells. It consists of an early cytomegalovirus promoter (CMV) 
for high level expression in HEK 293T cells. Presence of a neomycin-resistance gene 
enables selection of stable cell lines. The Simian Vacuolating Virus 40 Tag, a hexameric 
oncoprotein facilitates episomal replication in HEK 293T via the large SV40 larger T 
antigen, as described above.
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3.3.1 The Pro signal of NGF facilitates soluble expression of biologically- 
active NGF, determined by neurite outgrowth in PC-12 cells 
The objective of this experiment was to determine if NGF expressed in HEK 293T was 
biologically active.  
NGF binds to the high-affinity tyrosine kinase receptor, TrkA, leading to its 
phosphorylation and the subsequent activation of PI3K/Akt/GSK3β pathways. This, in 
turn, facilitates the cytoskeletal rearrangements necessary for neurite outgrowth 
(Patapoutian et al. 2001; Cantley et al. 2002; Zhou et al. 2004 and Hur et al. 2010; Sierra-
Fonseca et al 2014). The Chimeric construct pCDNA3.1pro.βNGF (Fig. 22A) containing 
the Pre-Pro.βNGF gene (Ullrich et al. 1983) was provided by Dr Anna Maria Colangelo 
(Università degli Studi di Milano-Bicocca).  
Due to the absence of a purification tag in the chimeric construct pCDNA3.1.Pre-
Pro.βNGF, affinity purification was not possible. Instead, it was decided to collect the 
conditioned medium transfected with the chimeric construct pCDNA3.1.Pre-Pro.βNGF. 
This conditioned medium was tested on PC-12 cells and neurite outgrowth of PC-12 cells 
was detected by bright field microscopy (Fig. 22C), suggesting the presence of soluble and 
biologically active NGF in the conditioned medium. This may have resulted from the 
presence of: (a) Pro signal in the design of pCDNA3.1Pro.βNGF (Lessmann et al. 2003; 
Danielsen 1990; Naim and Naim 1996; Rothman and Orci 1992; Presley et al 1997) (b) use 
of HEK 293T cells which contain the components necessary for post translational 
processing of Pro.NGF into soluble mature βNGF homodimer, as described above in 
Section 3.3 (Aricescu et al. 2006; Mancia et al. 2004). The presence of endogenous furin in 
HEK 293T cells was also considered as a (possible) contributing cause (Wang et al. 2004; 
Seidah et al. 1996). For comparison, the control medium from non-transfected cells was 
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tested on PC-12 cells; no neurite outgrowth of PC-12 cells was detected by bright field 
microscopy (Fig. 22B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22 Conditioned medium from pCDNA3.1Pro.βNGF transfected HEK 293T cells, 
but not from non-transfected cells, resulted in the growth of neurites from PC-12 
cells. (A) Schematic of chimera pCDNA3.1.Pro.βNGF. Representative micrographs, (B) PC-12 
cells exposed for three days to conditioned medium from non-transfected HEK 293T cells. (C) HEK 
293T transfected with pcDNA3.1.Pro.βNGF. Scale bar = 100 μm. 
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3.3.2 Generated chimera pCDNA3.1.Pro.Vamp2.βNGF and 
pCDNA3.1.Pro.βNGF.Vamp2: cloning and transfection 
To surmount the insolubility issue encountered previously for Trx.Vamp2.βNGF, I 
designed the chimeric construct pCDNA3.1.Pro.Vamp2.βNGF (Fig. 23A). The gene 
sequence encoding protein Pro.Vamp2.βNGF was synthesized and supplied by MWG 
Eurofins. It was inserted into the mammalian expression vector pCDNA3.1 within 
restriction endonuclease sites Hind III to Xho I (Fig. 23B). It is notable that this design 
included a his(6) tag to facilitate rapid affinity purification. This was inserted between the 
furin cleavage site and Vamp2 sequence so that mature Vamp2.βNGF could be captured. 
Sequencing of the resulting chimera (Appendix 2) confirmed the correct orientation of 
DNA encoding protein Pro.Vamp2.βNGF, beginning with methionine of Pre-Pro signal of 
NGF, within the translational frame of mammalian expression vector pCDNA3.1 (Fig. 
23C).  
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Fig. 23 Design and cloning 
pCDNA3.1.Pro.Vamp2.βNG
F and 
pCDNA3.1.Pro.βNGF.Vamp
2 (A) Chimeric construct 
pCDNA3.1.Pro.Vamp2.βNGF. 
The DNA encodes Pre-Pro 
signal peptide (black box), a furin 
cleavage site R 122 (pink box), 
which separates Pre-pro signal, 
10 amino acid 
(GGGGSGGGGS) flexible linker 
(white box), his(6) tag for IMAC 
purification (green box), Vamp2 
for SNARE stapling (red box), a 
second 10 amino acid 
(GGGGSGGGGS) flexible linker 
(white box), human βNGF gene 
(yellow box). A thrombin 
cleavage site G 143 allows 
removal of the his(6) tag following 
IMAC purification. (B) Agarose 
gel image stained with ethidium 
bromide. Lanes (L) represent 10 
kbp DNA ladder and vector 
pCDNA3.1. Pro.Vamp2.βNGF after double digestion with restriction endonucleases Hind III and 
Xho I for 1 hour at 37
◦
C. Two bands visualized indicate the presence of excised vector pCDNA3.1 
and insert Pro.Vamp2.βNGF at size 5.3 kbp and 1.003 kbp, respectively. 
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HEK 293T cells were transfected with pCDNA3.1.Pro.Vamp2.βNGF by using PEI. As 
determined using the BCA method (see section 2.2.4.4), IMAC purification yielded 9 μg of 
total protein from 100 ml of pooled conditioned medium post transfection. Upon SDS-
PAGE and Western blotting with antibodies against anti-Vamp 1, 2, 3, a band detected at 
molecular weight Mr ~35.5k corresponds to the expected migration of protein 
Pro.Vamp2.βNGF (Fig. 24 A,B). Western blotting using specific antibodies to phospho 
MAPK 42/44 and total MAPK 42/44 indicated that IMAC purified Pro.Vamp2.βNGF 
partially activated TrkA receptor (described in detail later in Fig. 25).  
To optimize the biological activity, it was decided to modify the design of 
Pro.Vamp2.βNGF by interchanging the βNGF and Vamp2 gene and introduce it within the 
mammalian expression vector, pCDNA3.1 (DNA Sequence of the chimera 
pCDNAR3.1.Pro.βNGF.Vamp2 is described in Appendix 3). The aim of creating chimera 
pCDNAR3.1.Pro.βNGF.Vamp2 (Fig. 24C) by interchanging βNGF and Vamp2 gene was 
to ascertain, if the biological activity could be improved by including precedent Pre-Pro 
sequences adjacent to NGF, as it occurs in its natural form, as described in Ullrich et al. 
(1983). The gene encoding Pro.βNGF.Vamp2 was inserted into the mammalian expression 
vector pCDNA3.1 within restriction endonuclease sites Hind III to Apa I (Fig. 24D). 
Chimera pCDNA3.1.Pro.βNGF.Vamp2 was transiently transfected onto the HEK 293T 
cells. Western blotting using specific antibodies to phospho MAPK 42/44 and total MAPK 
42/44 showed that, pCDNA3.1.Pro.βNGF.Vamp2, transfected conditioned medium from 
HEK293T cell culture activated TrkA mediated Ras, C-raf, MEK pathway (Fig. 25). 
Unfortunately, due to time constrains, scaling up of HEK 293T cells followed by IMAC 
purification could not be achieved. 
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Fig. 24 
Transfection of chimeras 
pCDNA3.1.Pro.Vamp2.βNGF and pCDNA3.1.Pro.βNGF.Vamp2 (A) Western blotting of 
Talon
®
 resin that has been incubated with conditioned medium ranging from neat to diluted in 
gradations 1:10, 1:15 and 1:20. Bands detected by specific antibody to Vamp 1,2,3 at Mr ~23.5 k 
and Mr~37.5 k indicate the presence of Linker.Vamp2.βNGF and Pro.Vamp2.βNGF, respectively. 
Bands determined at ~Mr 23.5 k maybe due to presence of endogenous furin activity present within 
HEK 293T cells. HEK 293T cells contain endogenous furin, which may have caused cleavage at 
the furin site to produce linker.Vamp2.βNGF. (B) Depicts Western blotting using antibodies against 
Vamp 1,2,3 following IMAC purification of conditioned medium from HEK293T cells transfected with 
pCDNA3.1.Pro.Vamp2. Conditioned medium (Total) was mixed with Talon resin at 4
◦
C for 1 hour 
before separating unbound proteins (FT) from the resin by gravity flow columns. After washing with 
wash buffer (150 mM NaCl, 20 mM HEPES and 10 mM imidazole), his(6) tagged proteins were 
eluted by 500 mM imidazole; eluted proteins were separated from imidazole. salt and buffer 
exchanged into storage buffer (20 mM HEPES, 145 mM NaCl pH 7.4) by gel filtration columns. The 
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expected bands at Mr ~23.5 k and Mr ~37.5 k were detected by antibody to Vamp1,2,3 indicating 
presence of protein Linker.Vamp2.βNGF and Pro.Vamp2.βNGF. (C) Schematic of mammalian 
expression vector pCDNA3.1.Pro.βNGF.Vamp2.  It encodes a single chain protein consisting of 
Pre-Pro signal peptide (black box), human βNGF gene (yellow box), 10 amino acid 
(GGGGSGGGGS) flexible linker (white box), six residues of histidine for IMAC purification (green 
box) and Vamp2 for SNARE stapling (red box). The Pre-Pro signal peptide can be cleaved in the 
presence of furin (pink box) shown by arrow at amino acid position R122. (D) Ethidium bromide 
stained agarose gel loaded with DNA Ladder (L) and vector pCDNA3.1.Pro.βNGF.Vamp2 after 
double digestion with restriction endonucleases Hind III and Apa I for 3 hour at 25
◦
C. The two 
bands indicate the presence of both double digested vector pCDNA3.1 and insert 
Pro.βNGF.Vamp2 at sizes 5.3 kbp and 1.027 kbp, respectively.
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 Proteins Vamp2.EGF and Pro.βNGF.Vamp2 induced 3.4
phosphorylation of MAPK 42/44 in SH-SY5Y cells suggesting 
activation of their requisite growth factor receptors. 
NGF binds to TrkA with high affinity (Kd = 10
-11
M). Binding of NGF to TrkA stimulates 
dimerization of the latter, leading to phosphorylation of ERK 42/44 via activation of 
intracellular proteins such as Ras, c-Raf and MEK. Similarly EGF binds to epidermal 
growth factor receptor (EGFR); leading to its dimerization which, in turn, results in 
phosphorylation of ERK 42/44 via intracellular proteins such as c-Raf, PI3 and MEK.  
SH-SY5Y cells have growth factors receptors such as TrkA and EGFR on their cell 
surfaces. The experiment discussed in this paragraph was performed as described in section 
2.2.7.1. The effects of the growth factors listed in Fig.25 on serum-starved SH-SY5Y cells 
showed bands at ~ Mr 42 k and Mr ~44 k (Fig. 25A) detected by antibodies, total ERK 
42/44 and phospho ERK 42/44, indicating the presence of total and phosphorylated 
MAPK, respectively. The bar chart (Fig. 25B) obtained after densitometric analysis of the 
bands detected using Image J shows the ratio of Phospho ERK to total ERK. The bar 
labelled (b) corresponds to protein 7S NGF, the positive control, known to activate Ras, C-
raf /MEK pathway via ERK 42/44 phosphorylation was used for comparison purposes. 
The ratio of phospho ERK 42/44 is a measure of the biological activity of the growth 
factors. Relative to 7S NGF (bar b), Vamp2.EGF (bar a) and Pro.βNGF.Vamp2 (bar g) 
gave approximately the same ratio indicating that both are biologically active. Similarly, 
relative to 7S NGF, Pro.Vamp2.βNGF (bars d and f) has approximately half the ratio 
suggesting that they were partially biologically active. This could be due to unavailability 
of free NGF N-termini to activate the TrkA receptors. The activity indicated in the proteins 
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corresponding to bars (f) and (g) arises from combination of the activity of the serum and 
the native biological activity of the proteins. 
 
 
 
 
 
 
 
Fig. 25 Chimeras encoding proteins 
Vamp2.EGF, Pro.Vamp2.βNGF and 
Pro.βNGF.Vamp2 show biological 
activity on neuroendocrine cells (A) 
Western blotting using specific antibodies 
to Total ERK 42/44 and phospho ERK 
42/44 after exposure to growth factors as 
fusion proteins, as listed in the key. (B) Ratio of phospho ERK to total ERK detected by antibodies. 
The intensities of immune-signals were measured from digitized images using NIH Image J 
software. All data plotted in (B) are means ± S.E.M., n = 2. 
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4 General discussion
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In this chapter many of the themes described in chapter 1 are elaborated and discussed in 
the light of the findings of this study. 
 Effectiveness of pharmacological therapies for chronic pain 4.1
Given the clinical problem presented by chronic pain, considerable effort has been 
expended in finding methods for its alleviation. The therapies most prescribed for 
alleviation of pain are classified into three categories: 1) Non-steroidal anti-inflammatory 
drugs (NSAIDs), which are commonly known as aspirin and ibuprofen; 2) Opioids, such as 
morphine and pre-gabalin and 3) Surgery (Foster et al. 1999). The pain relieving action of 
NSAIDs occurs by reducing the concentration of prostaglandins in the PNS. However, 
prostaglandins are only one of several mediators of pain (Dray A 1995); therefore, 
NSAIDSs are only effective in reducing mild pain. The uses of NSAIDs are associated 
with side effects such as initiation of ulceration in gastro-intestinal tract and gut which 
limit their use in chronic pain relief (Foster et al. 1999; Kalso et al. 2003; Foster et al. 
1999).  
Opioids act at the spinal cord level, inhibiting neurotransmission between primary 
nociceptive fibers (C fibers) and projection neurons; this is achieved by causing prolonged 
hyper-polarization at their synapses. Unfortunately, opioids have the following unwanted 
side effects (Foster et al. 1999): 1) depression of respiratory system in the brain stem; 2) 
constipation by effects on smooth musculature of gastro-intestinal tract; 3) psychoactive 
effects including sedation and euphoria and 4) physical dependence leading to drug abuse 
(e.g. heroine). 5) Tolerance to opioids i.e. increasing dose of drug required to produce the 
same analgesic effect). Surgical lesions of pain pathways at various levels from peripheral 
nerves through dorsal root section have been used for severe chronic pain. However, these 
surgical operations are associated with significant risk to patients. Therefore, there is an 
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unmet need for development of new class of pharmaceuticals for pain treatments. The 
desired properties of new therapies should 1) have the ability to provide long-lasting pain 
relief 2) lack systemic side-effects that impair patient’s quality of life (Foster et al. 1999).  
 Botulinum toxin as an emerging therapeutic 4.2
 Local injection of BOTOX
®
 (Allergan Inc., California) or its active component botulinum 
neurotoxin A (BoNT/A) has proved most successful in the treatment of human disorders 
such as dystonias, spasticity, over-active bladder, abnormalities of gastro-intestinal 
sphincters, hyper-hydrosis and sialorrhea  (Dolly et al. 2012; Aoki et al. 2011). Common to 
all of these applications is that the BoNTs are taken up in the motor neuron terminal at the 
neuromuscular junction or parasympathetic axon terminal where the toxin acts to block the 
release of acetylcholine (Pantano et al. 2014; Pellett et al. 2015).  Because of its 
remarkable effectiveness in alleviating numerous clinical conditions due to over-activity of 
nerves, research is being focused on other indications for this potent and specific inhibitor 
of exocytosis particularly in the area of pain (Mittal et al. 2016). The toxin has shown 
interesting analgesic activities on other neuronal pathways, including blockade of the 
release of pain mediators (glutamate, substance P, CRGP) from peripheral terminals, dorsal 
root ganglia (DRG), and spinal cord neurons (Lucioni et al. 2008; Meng J et al. 2007; Oh 
et al. 2015) decreasing local inflammation around nerve terminals (Cui et al. 2004; 
Kharatmal et al. 2015; Shin et al. 2012) inhibiting discharge of muscle spindles (Fillippi et 
al. 1993) and decreasing sympathetic transmission (Rand et al. 1965). Although the 
underlying mechanism is not as clearly understood as that for neuromuscular and other 
cholinergic conditions, it has led to the utilization of the toxin for various pain-related 
conditions such as myofascial pain syndrome and migraine (Moore et al. 2007; Masuyer et 
al. 2014).  
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Building on its success, described above, in the treatment with migraine, where it acts on 
sensory neurons, attempts have been made to apply it more widely. One such application 
involved replacing the binding domain of BoNT/A(HCC) with βNGF which  was hoped 
would bind and re-target the LC/A to sensory neurons, rather than motor neurons. This was 
the main focus of my research, in the attempt to create a conjugate of NGF with 
BoNT/A∆HCC (abbreviated as /A∆HCC).  
 Potential applications of re-engineered BoNT/A arising from this 4.3
study 
The potential applications of re-engineered BoNT/A arising from this study are discussed 
under three sub-headings. 
4.3.1 Discussion of BoNT based chimera /A∆HCC (first generation of 
recombinant proteins). 
This study involved direct fusion of NGF to BoNT using recombinant DNA technology to 
seek a cost-effective method for large scale production of such proteins. For this purpose, 
chimeric construct encoding NGF fused to /A∆HCC was created and expressed in E.coli 
(/A∆HCC consists of the light chain, translocation domain and N-terminal heavy chain of 
BoNT/A, without its binding domain). The resultant protein was purified using IMAC and 
its biological activity tested on PC-12 cells. Western blotting using antibodies to phospho 
ERK 42/44 yielded indirect evidence that receptor uptake of /A∆HCCN did not take place 
through the NGF high-affinity receptor, TrkA. Western blotting using specific antibodies 
to SNAP-25 indicated that at the higher concentrations tested (30 nM and 10 nM), 
/A∆HCCN protein showed cleavage of SNAP-25, but none at 3 nM. This could be due to 
non-specific binding and membrane uptake of /A∆HCCN protein by PC-12 cells. This 
avenue of research was not pursued further. 
  Chapter 4 
98 
   
βNGF homodimer is the biologically-active form of mature NGF. It binds to receptor TrkA 
with high affinity i.e. Kd =10 
-11
M. Protein Data Bank image of NGF-TrkA complex 
(Weismann et al. 2000) showed that the two N termini of the NGF homodimer are 
arranged parallel to each other. The N-termini, particularly residues 1-12, play an active 
role in the stimulation of the extracellular domain of TrkA receptor leading to its 
dimerization (Ullrich et al. 1983). This βNGF binding to TrkA, in turn, causes 
phosphorylation of threonine 202 and tyrosine 204 of MAPK via activation of Ras, C-raf, 
and MEK pathway. Herein, Western blotting using a specific antibody to phospho MAPK 
42/44 showed that /A∆HCCN did not lead to TrkA stimulated phosphorylation of MAPK 
proteins in PC-12 cells, indicating that it was biologically inactive.  
Regarding the design of the chimeric construct /A∆HCCN, the N-terminal of βNGF is not 
free but fused to a 10 amino acid flexible linker which conjugates it to domain HN.HCN.LC 
of BoNT/A; this could have occluded the critical N-terminal residues in such a way as to 
render them unavailable to stimulate the TrkA receptors. The first 8 N-terminal residues of 
LC/A not only contains a signal for localization to the plasma membrane but also 
contributes an important structural element of the protein (Aoki et al. 2003). Therefore it 
was considered preferable to have LC/A at the N-terminus rather than βNGF within the 
chimeric construct /A∆HCCN. Because the uni-directional nature of protein translation (N-
C terminus) was considered a major obstacle, it was concluded that a better method of 
producing active /A∆HCC was required. As a possible development for future studies, it is 
suggested that attaching fluorophore tags to /A∆HCCN, could serve as tracers to indicate the 
intracellular path of the /A∆HCCN in PC-12 cells.  
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4.3.2  Discussion of recombinant proteins, created using stapling 
technology (Second generation recombinant proteins). 
The discussion of recombinant proteins, created using stapling technology (second 
generation recombinant proteins) is sub-divided into three parts. 
4.3.2.1 LCHN/ A fragment 
Modular arrangement of BoNT and the independent functions of its three domains have 
encouraged several researchers to create variant BoNTs using recombinant DNA 
technology (Wang et al. 2008; Wang et al. 2011; Dolly et al. 2011; Dolly et al. 2014; 
Masuyer et al. 2014). Shone et al (1985) suggested that controlled proteolytic digestion of 
BoNT/A by trypsin results in the di-chain of LC/A and HN linked by di-sulphide bond 
named, the LCHN /A fragment. LCHN /A lacks the binding domain (HCC), which makes it 
non-toxic as it is unable to bind to neuronal receptors. Replacing the binding domain (HCC), 
with alternative ligands, the resultant fusion has been targeted to enter neuronal and non-
neuronal cells. The LCHN /A fragment maintains protease activity and blocks secretion 
from the targeted cells via the cleavage of SNAP-25 (Alexander et al. 2002; Foster et al. 
2006; Foster 2009). Under low pH conditions, the LCHN /A fragment forms pores through 
the endosomal membrane, although the pore-formation mechanism for translocation 
remains elusive. (Foster et al. 2006).  
4.3.2.2 The limitations of chemical coupling technology 
Chaddock et al (2000) have described the chemical conjugation of LC.HN/A to NGF and 
showed that this molecule was potent (IC50 for NGF-LCHN/A= 1.71 ±0.39 nM , BoNT/A = 
4.0 ± 1.27 nM, and LHN/A = 688 nM) in inhibiting neurotransmitter release from PC-12 
cells. Chemical conjugation of LC.HN/A to NGF has several disadvantages such as: 1) both 
components are sensitive to over-derivatization by their respective linkers; this has been 
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reported to reduce catalytic activity (Chaddock et al. 2000); 2) the formation of non-
specific aggregated proteins; 3) the need for several  purification steps such as size 
exclusion chromatography, cation exchange chromatography to separate conjugated 
product and 4) poor conjugation efficiency i.e.~ 250 μg of conjugated product from 2 mg 
of NGF and ~1 mg of LC.HN/A (Foster et al. 2015).  
4.3.2.3 The use of protein stapling technology  
As an alternative to chemical conjugation, Arsenault et al. (2013) suggested exploiting the 
established selective and high-affinity interaction of the α-helices from neuronal SNAREs 
to achieve biochemical coupling; this strategy has been termed protein stapling (Fig. 22). 
Four α-helices derived from three SNARE proteins such as SNAP-25 (22-206) Vamp2 (25-
84) and syntaxin-1 (1-40) spontaneously interact when mixed to form a tetra-helical tight 
interaction (Darrios et al. 2010). The assembled neuronal SNARE complex is 
extraordinarily stable, exhibiting resistance to chaotropic agents, strong detergents, 
proteases, and elevated temperatures as detailed in Section 1.3.3.2 of Chapter 1 of this 
study (Sutton 1998, Sudhof and Rothman 2009). Arsenault et al. (2013) created individual 
components Vamp2 (25-84) fused EGF and SNAP-25 (22-206) fused LC.HN/A in E.coli 
via DNA recombination.  They were stapled together into a functional unit by addition of a 
synthetic peptide corresponding in sequence to residues (1-45) of syntaxin-1.  
 
 
 
Fig. 26 Schematic representation of LC.HN/A.SNAP-25.syntaxin-1.Vamp2- βNGF. 
Stapling reaction using LCHN/A-SNAP-25 (the protease domain, brown; the translocation domain, 
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red, and a SNAP-25 (22-206) linker, green), the Vamp2 (25-84) linked to βNGF (yellow) and the 
syntaxin-1 peptide (1-45) (blue). Addition of the syntaxin-1 peptide (1-45) results in formation of an 
LC.HN/A.SNAP-25.syntaxin-1.Vamp2- βNGF (Image adapted from Arsenault et al. 2013). 
Herein, I successfully replicated the creation of Vamp2 fused to EGF in E.coli, and then 
attempted to replace the EGF with βNGF, and apply the protein stapling method. 
Unfortunately, the Trx.Vamp2.βNGF resulting from expression of the chimeric construct 
pET32b.Trx.Vamp2.βNGF appeared in the insoluble fraction of the lysates. It is proposed 
that the insolubility could be due to a lack of Pre-Pro signal protein in the design of the 
chimeric construct pET32b.Trx.Vamp2.βNGF resulting in the accumulation of incorrectly 
folded protein in the inclusion bodies. This explanation in relation to the insolubility of 
Trx.Vamp2.βNGF concurs with arguments given by Rattenhol et al. (2001) that Pro 
sequence of NGF promotes folding of the mature βNGF. Despite being very hydrophobic, 
naturally- occurring NGF is soluble. Lessmann et al. (2003) reported that soluble 
expression of biologically-active NGF is facilitated by the presence of its Pre-Pro signal 
protein. Because of the lack of success in expression of soluble βNGF fused to Vamp2 in 
E.coli, it became clear that exploration of this modification system was necessary.  
A paper by Colangelo et al. (2005) reported that transfection of the construct encoding Pre-
Pro.βNGF expressed soluble NGF in mammalian cells. I was able to achieve the 
expression of NGF using pCDNA3.1.Pre-Pro.βNGF kindly provided by Prof.Anna Maria 
Colangelo (Università degli Studi di Milano-Bicocca). This successful production of 
soluble biologically-active NGF encouraged me, to design two new constructs 1) 
pCNDA3.1Pro.Vamp2.βNGF and 2) pCNDA3.1Pro.βNGF.Vamp2, to transfect these into 
HEK 293T cells and to generate chimeric proteins Pro.Vamp2.βNGF and 
Pro.βNGF.Vamp2, respectively. As already stated in section 3.3.2 the IMAC purification 
of Pro.Vamp2.βNGF yielded 9 μg of total protein from 100 ml of pooled conditioned 
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medium. As already pointed out in section 3.3.2 scaling up of Pro.βNGF.Vamp2 in HEK 
293T cell culture followed by IMAC purification was not carried out. Notably, testing their 
biological activity on SH-SY5Y cells showed both Pro.Vamp2.βNGF and 
Pro.βNGF.Vamp2 were found to be active, detected by specific antibodies to total ERK 
and phospho ERK. Thus, the Pre-Pro signal can facilitate expression of soluble fusion 
protein containing a functional NGF moiety fused to a SNARE sequence that can be 
exploited for biochemical protein conjugation. The result may also be explained by the fact 
that HEK 293 cells contain the necessary components for soluble expression of proteins 
Pro.Vamp2.βNGF and Pro.βNGF.Vamp2. Chen et al. (2011) reported that the N terminal 
residues (1 -12) of βNGF played an important role in activating TrkA receptor. In this 
regard, it should be noted that cleavage of Pre-Pro signal from Pro.βNGF. Vamp2 by 
endogenous furin in HEK 293 cells would produce βNGF.Vamp2 with the N-terminal of 
βNGF.Vamp2 free to stimulate TrkA receptors and was identified as the core finding in 
this study. 
4.3.3 Future work 
The strategy for direct fusion of βNGF to LC.HN.HCN/A by genetic recombination was 
unsuccessful as demonstrated by the fact that LC.HN.HCN/A.βNGF generated was 
biologically inactive. Although protein stapling technology proved promising, the stapling 
of βNGF.Vamp2 to LC.HN.SNAP-25 was not performed due to time constraints. If more 
time had been available, I would have proceeded to optimize the yield of βNGF.Vamp2, 
leading to the following future options: 1) to scale up the amount of conditioned medium 
with Pro.βNGF.Vamp2 by selecting stable HEK 293 cells transfected with 
pCDNA3.1.Pro.βNGF.Vamp2 (Lonza 2016); followed by protein purification via IMAC 
and protein analysis by SDS-PAGE and Western blotting (as described in Chapter 2), 2) to 
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generate βNGF.Vamp2 by nicking Pro.βNGF.Vamp2 using commercial furin, 3) to staple 
βNGF.Vamp2 to LC.HN.SNAP-25 by addition of syntaxin-1 fused to fluorophore like 
FITC as described in Ferrari et al (2012). Currently, both LC.HN.SNAP-25 and syntaxin-
1.fused to fluorophore like FITC have been synthesized and are available in ICNT and 4) 
to test the biological activity of stapled product on PC-12 cells using assays such as i.e. 
ERK phosphorylation and SNAP-25 cleavage, as described in Chapter 2. Syntaxin-1.fused 
to FITC would be advantageous as it could act as a tracer to indicate the specific 
intracellular path of the stapled product in PC-12 cells. 
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Appendix 1 – Sequenced DNA of pET32b Trx./A∆HCCN  
     TGGCGAATGG GACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG        
60 
     CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC       
120 
     CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC TCCCTTTAGG       
180 
     GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC       
240 
     ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT       
300 
     CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC AACCCTATCT CGGTCTATTC       
360 
     TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA       
420 
     ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT ACAATTTCAG GTGGCACTTT       
480 
     TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA       
540 
     TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAGAGTAT       
600 
     GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT       
660 
     TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT GAAGATCAGT TGGGTGCACG       
720 
     AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA       
780 
     AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG       
840 
     TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA ATGACTTGGT       
900 
     TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG       
960 
     CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA CAACGATCGG      
1020 
     AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGA      
1080 
     TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA CCACGATGCC      
1140 
     TGCAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC GAACTACTTA CTCTAGCTTC      
1200 
     CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC TTCTGCGCTC      
1260 
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     GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA GCCGGTGAGC GTGGGTCTCG      
1320 
     CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG TTATCTACAC      
1380 
     GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA TAGGTGCCTC      
1440 
     ACTGATTAAG CATTGGTAAC TGTCAGACCA AGTTTACTCA TATATACTTT AGATTGATTT      
1500 
     AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAC      
1560 
     CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTAG AAAAGATCAA      
1620 
     AGGATCTTCT TGAGATCCTT TTTTTCTGCG CGTAATCTGC TGCTTGCAAA CAAAAAAACC      
1680 
     ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT TTCCGAAGGT      
1740 
     AACTGGCTTC AGCAGAGCGC AGATACCAAA TACTGTCCTT CTAGTGTAGC CGTAGTTAGG      
1800 
     CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA TCCTGTTACC      
1860 
     AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA GACGATAGTT      
1920 
     ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTCG TGCACACAGC CCAGCTTGGA      
1980 
     GCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG CTATGAGAAA GCGCCACGCT      
2040 
     TCCCGAAGGG AGAAAGGCGG ACAGGTATCC GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG      
2100 
     CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA      
2160 
     CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC TATGGAAAAA      
2220 
     CGCCAGCAAC GCGGCCTTTT TACGGTTCCT GGCCTTTTGC TGGCCTTTTG CTCACATGTT      
2280 
     CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCTTTG AGTGAGCTGA      
2340 
     TACCGCTCGC CGCAGCCGAA CGACCGAGCG CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA      
2400 
     GCGCCTGATG CGGTATTTTC TCCTTACGCA TCTGTGCGGT ATTTCACACC GCATATATGG      
2460 
     TGCACTCTCA GTACAATCTG CTCTGATGCC GCATAGTTAA GCCAGTATAC ACTCCGCTAT      
2520 
     CGCTACGTGA CTGGGTCATG GCTGCGCCCC GACACCCGCC AACACCCGCT GACGCGCCCT      
2580 
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     GACGGGCTTG TCTGCTCCCG GCATCCGCTT ACAGACAAGC TGTGACCGTC TCCGGGAGCT      
2640 
     GCATGTGTCA GAGGTTTTCA CCGTCATCAC CGAAACGCGC GAGGCAGCTG CGGTAAAGCT      
2700 
     CATCAGCGTG GTCGTGAAGC GATTCACAGA TGTCTGCCTG TTCATCCGCG TCCAGCTCGT      
2760 
     TGAGTTTCTC CAGAAGCGTT AATGTCTGGC TTCTGATAAA GCGGGCCATG TTAAGGGCGG      
2820 
     TTTTTTCCTG TTTGGTCACT GATGCCTCCG TGTAAGGGGG ATTTCTGTTC ATGGGGGTAA      
2880 
     TGATACCGAT GAAACGAGAG AGGATGCTCA CGATACGGGT TACTGATGAT GAACATGCCC      
2940 
     GGTTACTGGA ACGTTGTGAG GGTAAACAAC TGGCGGTATG GATGCGGCGG GACCAGAGAA      
3000 
     AAATCACTCA GGGTCAATGC CAGCGCTTCG TTAATACAGA TGTAGGTGTT CCACAGGGTA      
3060 
     GCCAGCAGCA TCCTGCGATG CAGATCCGGA ACATAATGGT GCAGGGCGCT GACTTCCGCG      
3120 
     TTTCCAGACT TTACGAAACA CGGAAACCGA AGACCATTCA TGTTGTTGCT CAGGTCGCAG      
3180 
     ACGTTTTGCA GCAGCAGTCG CTTCACGTTC GCTCGCGTAT CGGTGATTCA TTCTGCTAAC      
3240 
     CAGTAAGGCA ACCCCGCCAG CCTAGCCGGG TCCTCAACGA CAGGAGCACG ATCATGCGCA      
3300 
     CCCGTGGGGC CGCCATGCCG GCGATAATGG CCTGCTTCTC GCCGAAACGT TTGGTGGCGG      
3360 
     GACCAGTGAC GAAGGCTTGA GCGAGGGCGT GCAAGATTCC GAATACCGCA AGCGACAGGC      
3420 
     CGATCATCGT CGCGCTCCAG CGAAAGCGGT CCTCGCCGAA AATGACCCAG AGCGCTGCCG      
3480 
     GCACCTGTCC TACGAGTTGC ATGATAAAGA AGACAGTCAT AAGTGCGGCG ACGATAGTCA      
3540 
     TGCCCCGCGC CCACCGGAAG GAGCTGACTG GGTTGAAGGC TCTCAAGGGC ATCGGTCGAG      
3600 
     ATCCCGGTGC CTAATGAGTG AGCTAACTTA CATTAATTGC GTTGCGCTCA CTGCCCGCTT      
3660 
     TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT CGGCCAACGC GCGGGGAGAG      
3720 
     GCGGTTTGCG TATTGGGCGC CAGGGTGGTT TTTCTTTTCA CCAGTGAGAC GGGCAACAGC      
3780 
     TGATTGCCCT TCACCGCCTG GCCCTGAGAG AGTTGCAGCA AGCGGTCCAC GCTGGTTTGC      
3840 
     CCCAGCAGGC GAAAATCCTG TTTGATGGTG GTTAACGGCG GGATATAACA TGAGCTGTCT      
3900 
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     TCGGTATCGT CGTATCCCAC TACCGAGATG TCCGCACCAA CGCGCAGCCC GGACTCGGTA      
3960 
     ATGGCGCGCA TTGCGCCCAG CGCCATCTGA TCGTTGGCAA CCAGCATCGC AGTGGGAACG      
4020 
     ATGCCCTCAT TCAGCATTTG CATGGTTTGT TGAAAACCGG ACATGGCACT CCAGTCGCCT      
4080 
     TCCCGTTCCG CTATCGGCTG AATTTGATTG CGAGTGAGAT ATTTATGCCA GCCAGCCAGA      
4140 
     CGCAGACGCG CCGAGACAGA ACTTAATGGG CCCGCTAACA GCGCGATTTG CTGGTGACCC      
4200 
     AATGCGACCA GATGCTCCAC GCCCAGTCGC GTACCGTCTT CATGGGAGAA AATAATACTG      
4260 
     TTGATGGGTG TCTGGTCAGA GACATCAAGA AATAACGCCG GAACATTAGT GCAGGCAGCT      
4320 
     TCCACAGCAA TGGCATCCTG GTCATCCAGC GGATAGTTAA TGATCAGCCC ACTGACGCGT      
4380 
     TGCGCGAGAA GATTGTGCAC CGCCGCTTTA CAGGCTTCGA CGCCGCTTCG TTCTACCATC      
4440 
     GACACCACCA CGCTGGCACC CAGTTGATCG GCGCGAGATT TAATCGCCGC GACAATTTGC      
4500 
     GACGGCGCGT GCAGGGCCAG ACTGGAGGTG GCAACGCCAA TCAGCAACGA CTGTTTGCCC      
4560 
     GCCAGTTGTT GTGCCACGCG GTTGGGAATG TAATTCAGCT CCGCCATCGC CGCTTCCACT      
4620 
     TTTTCCCGCG TTTTCGCAGA AACGTGGCTG GCCTGGTTCA CCACGCGGGA AACGGTCTGA      
4680 
     TAAGAGACAC CGGCATACTC TGCGACATCG TATAACGTTA CTGGTTTCAC ATTCACCACC      
4740 
     CTGAATTGAC TCTCTTCCGG GCGCTATCAT GCCATACCGC GAAAGGTTTT GCGCCATTCG      
4800 
     ATGGTGTCCG GGATCTCGAC GCTCTCCCTT ATGCGACTCC TGCATTAGGA AGCAGCCCAG      
4860 
     TAGTAGGTTG AGGCCGTTGA GCACCGCCGC CGCAAGGAAT GGTGCATGCA AGGAGATGGC      
4920 
     GCCCAACAGT CCCCCGGCCA CGGGGCCTGC CACCATACCC ACGCCGAAAC AAGCGCTCAT      
4980 
     GAGCCCGAAG TGGCGAGCCC GATCTTCCCC ATCGGTGATG TCGGCGATAT AGGCGCCAGC      
5040 
     AACCGCACCT GTGGCGCCGG TGATGCCGGC CACGATGCGT CCGGCGTAGA GGATCGAGAT      
5100 
 
 
     CGATCTCGAT CCCGCGAAAT TAATACGACT CACTATAGGG GAATTGTGAG CGGATAACAA      
5160 
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     TTCCCCTCTA GAAATAATTT TGTTTAACTT TAAGAAGGAG ATATACATAT GAGCGATAAA      
5220 
     ATTATTCACC TGACTGACGA CAGTTTTGAC ACGGATGTAC TCAAAGCGGA CGGGGCGATC      
5280 
     CTCGTCGATT TCTGGGCAGA GTGGTGCGGT CCGTGCAAAA TGATCGCCCC GATTCTGGAT      
5340 
     GAAATCGCTG ACGAATATCA GGGCAAACTG ACCGTTGCAA AACTGAACAT CGATCAAAAC      
5400 
     CCTGGCACTG CGCCGAAATA TGGCATCCGT GGTATCCCGA CTCTGCTGCT GTTCAAAAAC      
5460 
     GGTGAAGTGG CGGCAACCAA AGTGGGTGCA CTGTCTAAAG GTCAGTTGAA AGAGTTCCTC      
5520 
 
 
     GACGCTAACC TGGCCGGTTC TGGTTCTGGC CATATGCACC ATCATCATCA TCATTCTTCT      
5580 
 
 
     GGTCTGGTGC CACGCGGTTC TGGTATGAAA GAAACCGCTG CTGCTAAATT CGAACGCCAG      
5640 
 
     CACATGGACA GCCCAGATCA CGACGACGAC GACAAGATGC CGTTCGTAAA CAAACAGTTC      
5700 
     AACTATAAAG ACCCAGTCAA CGGCGTGGAC ATTGCCTATA TCAAAATCCC GAATGCGGGT      
5760 
     CAAATGCAGC CCGTGAAAGC ATTTAAAATC CATAACAAAA TTTGGGTGAT CCCGGAGCGC      
5820 
     GATACGTTCA CGAACCCGGA AGAAGGAGAT TTAAACCCAC CGCCTGAGGC TAAACAGGTC      
5880 
     CCGGTGTCTT ACTATGATAG CACATACCTG AGTACCGACA ATGAAAAGGA CAACTACCTG      
5940 
     AAAGGTGTTA CCAAACTGTT CGAGCGCATT TATTCGACAG ATCTCGGTCG CATGTTGCTG      
6000 
     ACTTCTATTG TGCGCGGCAT TCCGTTTTGG GGTGGTAGCA CCATCGATAC AGAACTCAAA      
6060 
     GTGATTGACA CCAACTGCAT CAATGTGATT CAGCCTGATG GGAGCTACCG GTCCGAAGAG      
6120 
     CTTAACCTCG TAATCATTGG CCCGAGCGCG GATATTATCC AATTCGAATG TAAATCTTTT      
6180 
     GGGCATGAAG TCCTGAATCT GACGCGGAAT GGCTATGGAT CGACGCAGTA TATTCGTTTT      
6240 
     TCTCCAGATT TCACATTTGG ATTTGAAGAA AGCCTCGAAG TTGATACGAA CCCTCTTTTA      
6300 
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     GGCGCGGGAA AATTCGCGAC GGACCCAGCG GTGACCTTGG CACATGAACT TATTCATGCC      
6360 
     GGGCATCGCT TGTATGGAAT CGCCATTAAC CCGAACCGTG TTTTCAAGGT GAATACGAAC      
6420 
     GCGTATTACG AGATGTCGGG CTTAGAAGTG TCCTTTGAAG AACTGCGCAC GTTTGGCGGT      
6480 
     CATGATGCAA AATTTATTGA TAGTCTGCAA GAAAACGAAT TTCGGCTGTA CTATTACAAT      
6540 
     AAATTCAAAG ACATTGCATC AACCTTAAAC AAGGCGAAAA GCATTGTGGG TACCACGGCT      
6600 
     AGCTTACAAT ATATGAAAAA CGTTTTCAAA GAAAAATACC TCCTTAGCGA AGACACTTCC      
6660 
     GGCAAATTCT CTGTCGATAA ACTGAAATTT GATAAACTGT ATAAAATGCT CACCGAGATC      
6720 
     TACACAGAGG ATAACTTTGT CAAATTCTTC AAGGTCTTGA ATCGGAAAAC CTATCTGAAC      
6780 
     TTCGATAAAG CCGTCTTTAA GATCAACATC GTACCGAAAG TTAACTACAC CATCTATGAT      
6840 
     GGCTTTAATC TGCGCAATAC GAATCTGGCG GCGAACTTTA ACGGCCAGAA CACCGAAATC      
6900 
     AACAACATGA ACTTTACTAA ACTGAAAAAT TTTACCGGCT TGTTTGAATT TTATAAGCTC      
6960 
     CTGTGTGTCC GCGGTATTAT CACCAGCAAA ACCAAATCCT TGGTGCCCCG CGGCTCTAAC      
7020 
     AAGGCGCTCA ATGATTTATG CATCAAGGTG AACAACTGGG ACTTGTTTTT CTCTCCATCT      
7080 
     GAAGATAATT TTACTAACGA CTTGAACAAA GGAGAGGAAA TTACTTCCGA TACCAACATC      
7140 
     GAAGCAGCGG AAGAGAATAT TAGCCTGGAT CTTATTCAAC AATATTACCT GACCTTTAAT      
7200 
     TTTGATAACG AGCCTGAGAA CATTTCCATT GAGAATCTCA GCTCTGACAT CATCGGCCAG      
7260 
     CTGGAACTGA TGCCGAATAT CGAACGCTTT CCTAATGGAA AGAAATATGA ATTGGACAAA      
7320 
     TACACCATGT TCCACTATCT CCGCGCGCAG GAGTTTGAGC ACGGCAAGTC TCGTATTGCT      
7380 
     CTGACCAATT CGGTAAACGA AGCCCTTTTA AATCCTTCGC GTGTGTACAC CTTTTTCTCA      
7440 
     AGCGATTATG TTAAAAAAGT GAACAAGGCG ACCGAAGCGG CGATGTTTTT GGGATGGGTG      
7500 
     GAACAACTGG TATATGACTT TACGGATGAA ACTTCTGAAG TCTCGACCAC CGACAAAATT      
7560 
     GCCGATATTA CCATTATCAT TCCCTATATT GGCCCTGCAC TGAACATTGG TAACATGCTG      
7620 
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     TATAAAGATG ATTTTGTGGG CGCCCTGATC TTTTCAGGCG CTGTTATCCT GCTGGAATTT      
7680 
     ATCCCGGAAA TCGCCATTCC AGTACTCGGT ACCTTTGCGC TGGTGTCCTA TATCGCAAAC      
7740 
     AAAGTTTTGA CTGTCCAGAC GATCGACAAC GCGCTCAGTA AACGTAACGA AAAATGGGAT      
7800 
     GAGGTGTATA AGTATATTGT TACCAACTGG CTCGCTAAAG TAAACACCCA GATTGACCTG      
7860 
     ATTCGCAAGA AGATGAAAGA AGCGCTGGAA AACCAAGCAG AAGCGACCAA AGCTATTATC      
7920 
     AACTATCAAT ATAACCAGTA CACAGAGGAA GAAAAGAATA ACATCAACTT CAACATCGAC      
7980 
     GACTTATCTT CAAAGCTGAA TGAATCTATT AACAAAGCGA TGATTAATAT TAACAAGTTC      
8040 
     TTGAACCAAT GTAGTGTCAG CTATCTGATG AACTCGATGA TCCCATATGG TGTGAAACGT      
8100 
     CTGGAAGACT TCGATGCAAG CCTTAAAGAT GCCCTTCTGA AGTATATTTA CGATAATCGC      
8160 
     GGAACTCTTA TTGGCCAAGT GGATCGCTTA AAAGATAAAG TCAACAACAC GCTGAGTACA      
8220 
     GACATCCCTT TTCAGCTGTC TAAATATGTG GACAATCAGC GCCTGCTGTC CACGTTTACG      
8280 
     GAATACATCA AAAACATCAT CAACACTAGT ATTCTGAACT TGCGTTACGA GAGTAACCAT      
8340 
     CTGATTGATC TGAGCCGTTA CGCATCTAAA ATCAACATCG GCTCGAAGGT GAACTTCGAT      
8400 
     CCTATCGACA AAAACCAGAT TCAATTGTTC AACTTAGAAT CGTCAAAGAT TGAAGTTATC      
8460 
     TTAAAAAATG CGATTGTATA TAATTCAATG TACGAAAATT TCTCTACGAG CTTTTGGATT      
8520 
     CGTATTCCGA AATATTTCAA CAGTATCTCT TTAAACAACG AGTATACTAT CATCAATTGT      
8580 
     ATGGAGAATA ACAGCGGGTG GAAAGTGAGC CTTAACTATG GTGAAATCAT CTGGACTCTG      
8640 
     CAGGACACTC AAGAAATTAA ACAACGCGTG GTGTTTAAAT ACTCACAGAT GATTAACATC      
8700 
     TCGGATTATA TTAATCGCTG GATTTTTGTG ACAATTACTA ACAACCGGCT GAACAACAGC      
8760 
     AAAATTTACA TTAACGGTCG CCTGATCGAT CAGAAACCAA TCAGTAATCT CGGTAACATT      
8820 
     CACGCATCGA ATAATATCAT GTTCAAACTG GATGGTTGTC GCGACACGCA CCGTTACATT      
8880 
     TGGATCAAAT ACTTCAATTT ATTCGACAAA GAACTCAACG AAAAGGAGAT TAAGGATCTT      
8940 
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     TATGACAATC AGTCTGAGCT CGGTGGTGGT GGTAGCGGTG GTGGCGGTTC AGGTGGTGGT      
9000 
     GGCAGTGGAT CCAGCAGCAG CCATCCGATT TTTCATCGTG GTGAATTTTC AGTTTGTGAT      
9060 
     AGCGTTAGCG TTTGGGTTGG TGATAAAACC ACCGCAACCG ATATTAAAGG TAAAGAAGTT      
9120 
     ATGGTTCTGG GCGAGGTGAA TATTAACAAC AGCGTTTTCA AACAGTATTT CTTTGAAACC      
9180 
     AAATGCCGTG ATCCGAATCC GGTTGATAGC GGTTGTCGTG GTATTGATAG CAAACATTGG      
9240 
     AATAGCTATT GTACCACCAC CCACACCTTT GTTAAAGCAC TGACCATGGA TGGTAAACAG      
9300 
     GCAGCATGGC GTTTTATTCG TATTGATACC GCATGTGTTT GTGTGCTGAG CCGTAAAGCA      
9360 
 
 
     GTTCGTCGTG CATAACTCGA GCACCACCAC CACCACCACT GAGATCCGGC TGCTAACAAA      
9420 
     GCCCGAAAGG AAGCTGAGTT GGCTGCTGCC ACCGCTGAGC AATAACTAGC ATAACCCCTT      
9480 
     GGGGCCTCTA AACGGGTCTT GAGGGGTTTT TTGCTGAAAG GAGGAACTAT ATCCGGATTC      
9540 
     TAGA                                                                   
9544 
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Appendix 2 – Sequenced DNA of pCDNA3.1 Pro.VAMP2.βNGF  
Appendix 2 
     GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG        
60 
     CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG       
120 
     CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC       
180 
     TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT       
240 
     GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA       
300 
     TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC       
360 
     CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC       
420 
     ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT       
480 
     ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT       
540 
     ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA       
600 
     TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG       
660 
     ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC       
720 
     AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG       
780 
     GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA       
840 
 
 
 
 
     CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC       
900 
 
 
 
 
     GTTTAAACTT AAGCTTATGT CAATGCTGTT CTATACGCTT ATCACGGCCT TTCTGATCGG       
960 
     TATACAGGCC GAACCTCATT CCGAGTCTAA CGTGCCTGCA GGCCACACAA TACCACAGGT      
1020 
     CCACTGGACC AAATTGCAGC ATTCCCTGGA CACTGCGTTG CGAAGGGCTA GAAGTGCCCC      
1080 
     TGCCGCTGCC ATTGCCGCAA GAGTCGCTGG ACAGACTCGG AATATTACTG TGGATCCACG      
1140 
     CCTGTTCAAG AAGAGGCGGC TCAGATCTCC CAGGGTGCTG TTCAGCACGC AACCACCAAG      
1200 
     AGAGGCAGCT GATACCCAGG ACCTGGATTT TGAAGTGGGT GGCGCTGCTC CCTTTAACCG      
1260 
 
 
 
 
     GACTCACAGG AGCAAGAGAG GCGGCGGCGG CTCTGGTGGA GGAGGGTCCC ACCATCACCA      
1320 
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     CCATCATCTC GTTCCTCGGG GCAGCAATCT CGCATCCAAT CGACGCTTGC AGCAGACACA      
1380 
     GGCTCAAGTG GATGAGGTCG TCGACATTAT GCGAGTGAAT GTTGACAAGG TACTCGAACG      
1440 
     CGATCAGAAG CTGAGTGAGC TGGACGACAG GGCGGATGCC CTTCAAGCTG GGGCCTCACA      
1500 
     GTTCGAGACA TCAGCCGCAA AACTGGGCGG AGGAGGGAGT GGTGGTGGCG GAAGCTCCTC      
1560 
 
 
     TTCTCATCCC ATCTTTCACC GTGGGGAGTT TAGCGTCTGT GACTCTGTGA GCGTATGGGT      
1620 
     TGGGGACAAA ACCACAGCCA CCGACATCAA AGGCAAGGAA GTGATGGTGC TGGGAGAAGT      
1680 
     CAACATCAAC AACAGCGTTT TCAAGCAGTA CTTCTTCGAG ACTAAATGCC GGGATCCGAA      
1740 
     TCCCGTGGAT TCAGGGTGTC GGGGAATTGA CAGCAAGCAC TGGAACAGTT ACTGCACCAC      
1800 
     CACACACACC TTCGTGAAAG CCCTGACAAT GGACGGGAAG CAAGCAGCAT GGCGCTTTAT      
1860 
 
 
     CCGTATTGAT ACCGCCTGTG TGTGCGTACT TTCCAGGAAA GCCGTTCGCA GAGCGTAACT      
1920 
 
 
     CGAGTCTAGA GGGCCCGTTT AAACCCGCTG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA      
1980 
     GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC      
2040 
     TGTCCTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT      
2100 
     TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA      
2160 
     TGCTGGGGAT GCGGTGGGCT CTATGGCTTC TGAGGCGGAA AGAACCAGCT GGGGCTCTAG      
2220 
     GGGGTATCCC CACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG      
2280 
     CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC      
2340 
     CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC TCCCTTTAGG      
2400 
     GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC      
2460 
     ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT      
2520 
     CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC AACCCTATCT CGGTCTATTC      
2580 
     TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA      
2640 
     ACAAAAATTT AACGCGAATT AATTCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC      
2700 
     CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCAGG      
2760 
     TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCATGCA TCTCAATTAG      
2820 
     TCAGCAACCA TAGTCCCGCC CCTAACTCCG CCCATCCCGC CCCTAACTCC GCCCAGTTCC      
2880 
     GCCCATTCTC CGCCCCATGG CTGACTAATT TTTTTTATTT ATGCAGAGGC CGAGGCCGCC      
2940 
     TCTGCCTCTG AGCTATTCCA GAAGTAGTGA GGAGGCTTTT TTGGAGGCCT AGGCTTTTGC      
3000 
     AAAAAGCTCC CGGGAGCTTG TATATCCATT TTCGGATCTG ATCAAGAGAC AGGATGAGGA      
3060 
     TCGTTTCGCA TGATTGAACA AGATGGATTG CACGCAGGTT CTCCGGCCGC TTGGGTGGAG      
3120 
     AGGCTATTCG GCTATGACTG GGCACAACAG ACAATCGGCT GCTCTGATGC CGCCGTGTTC      
3180 
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     CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG      
3240 
     AATGAACTGC AGGACGAGGC AGCGCGGCTA TCGTGGCTGG CCACGACGGG CGTTCCTTGC      
3300 
     GCAGCTGTGC TCGACGTTGT CACTGAAGCG GGAAGGGACT GGCTGCTATT GGGCGAAGTG      
3360 
     CCGGGGCAGG ATCTCCTGTC ATCTCACCTT GCTCCTGCCG AGAAAGTATC CATCATGGCT      
3420 
     GATGCAATGC GGCGGCTGCA TACGCTTGAT CCGGCTACCT GCCCATTCGA CCACCAAGCG      
3480 
     AAACATCGCA TCGAGCGAGC ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT      
3540 
     CTGGACGAAG AGCATCAGGG GCTCGCGCCA GCCGAACTGT TCGCCAGGCT CAAGGCGCGC      
3600 
     ATGCCCGACG GCGAGGATCT CGTCGTGACC CATGGCGATG CCTGCTTGCC GAATATCATG      
3660 
     GTGGAAAATG GCCGCTTTTC TGGATTCATC GACTGTGGCC GGCTGGGTGT GGCGGACCGC      
3720 
     TATCAGGACA TAGCGTTGGC TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT      
3780 
     GACCGCTTCC TCGTGCTTTA CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT      
3840 
     CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA CTCTGGGGTT CGAAATGACC GACCAAGCGA      
3900 
     CGCCCAACCT GCCATCACGA GATTTCGATT CCACCGCCGC CTTCTATGAA AGGTTGGGCT      
3960 
     TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA GCGCGGGGAT CTCATGCTGG      
4020 
     AGTTCTTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA      
4080 
     GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA      
4140 
     AACTCATCAA TGTATCTTAT CATGTCTGTA TACCGTCGAC CTCTAGCTAG AGCTTGGCGT      
4200 
     AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA      
4260 
     TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT      
4320 
     TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC CAGCTGCATT      
4380 
     AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT      
4440 
     CGCTCACTGA CTCGCTGCGC TCGGTCGTTC GGCTGCGGCG AGCGGTATCA GCTCACTCAA      
4500 
     AGGCGGTAAT ACGGTTATCC ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGTGAGCAA      
4560 
     AAGGCCAGCA AAAGGCCAGG AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC      
4620 
     TCCGCCCCCC TGACGAGCAT CACAAAAATC GACGCTCAAG TCAGAGGTGG CGAAACCCGA      
4680 
     CAGGACTATA AAGATACCAG GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC      
4740 
     CGACCCTGCC GCTTACCGGA TACCTGTCCG CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT      
4800 
     CTCATAGCTC ACGCTGTAGG TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT      
4860 
     GTGTGCACGA ACCCCCCGTT CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG      
4920 
     AGTCCAACCC GGTAAGACAC GACTTATCGC CACTGGCAGC AGCCACTGGT AACAGGATTA      
4980 
     GCAGAGCGAG GTATGTAGGC GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT      
5040 
     ACACTAGAAG AACAGTATTT GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA      
5100 
     GAGTTGGTAG CTCTTGATCC GGCAAACAAA CCACCGCTGG TAGCGGTTTT TTTGTTTGCA      
5160 
     AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG      
5220 
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     GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA      
5280 
     AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA      
5340 
     TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG      
5400 
     CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA      
5460 
     TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC      
5520 
     CGGCTCCAGA TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC      
5580 
     CTGCAACTTT ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA      
5640 
     GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC      
5700 
     GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT      
5760 
     GATCCCCCAT GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA      
5820 
     GTAAGTTGGC CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG      
5880 
     TCATGCCATC CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG      
5940 
     AATAGTGTAT GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC      
6000 
     CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT      
6060 
     CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT      
6120 
     CTTCAGCATC TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG      
6180 
     CCGCAAAAAA GGGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC      
6240 
     AATATTATTG AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA      
6300 
     TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGACG      
6360 
     TC  
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Appendix 3 - Sequenced DNA of pCDNA3.1 Pro.βNGF. VAMP2. 
GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG        60 
     CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG       
120 
     CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC       
180 
     TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT       
240 
     GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA       
300 
     TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC       
360 
     CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC       
420 
     ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT       
480 
     ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT       
540 
     ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA       
600 
     TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG       
660 
     ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC       
720 
     AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG       
780 
     GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA       
840 
 
 
 
 
     CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC       
900 
 
 
 
 
     GTTTAAACTT AAGCTTATGT CCATGTTGTT CTACACTCTG ATCACAGCTT TTCTGATCGG       
960 
     CATACAGGCG GAACCACACT CAGAGAGCAA TGTCCCTGCA GGACACACCA TCCCCCAAGT      
1020 
     CCACTGGACT AAACTTCAGC ATTCCCTTGA CACTGCCCTT CGCAGAGCCC GCAGCGCCCC      
1080 
     GGCAGCGGCG ATAGCTGCAC GCGTGGCGGG GCAGACCCGC AACATTACTG TGGACCCCAG      
1140 
     GCTGTTTAAA AAGCGGCGAC TCCGTTCACC CCGTGTGCTG TTTAGCACCC AGCCTCCCCG      
1200 
     TGAAGCTGCA GACACTCAGG ATCTGGACTT CGAGGTCGGT GGTGCTGCCC CCTTCAACAG      
1260 
     GACTCACAGG AGCAAGCGGT CATCATCCCA TCCCATCTTC CACAGGGGCG AATTCTCGGT      
1320 
     GTGTGACAGT GTCAGCGTGT GGGTTGGGGA TAAGACCACC GCCACAGACA TCAAGGGCAA      
1380 
     GGAGGTGATG GTGTTGGGAG AGGTGAACAT TAACAACAGT GTATTCAAAC AGTACTTTTT      
1440 
     TGAGACCAAG TGCCGGGACC CAAATCCCGT TGACAGCGGG TGCCGGGGCA TTGACTCAAA      
1500 
     GCACTGGAAC TCATATTGTA CCACGACTCA CACCTTTGTC AAGGCGCTGA CCATGGATGG      
1560 
     CAAGCAGGCT GCCTGGCGGT TTATCCGGAT AGATACGGCC TGTGTGTGTG TGCTCAGCAG      
1620 
 
 
 
#1 
#2 
#3 
#4 
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     GAAGGCTGTG AGAAGAGCCC TCGAGGGCGG CGGCGGCTCT GGTGGAGGAG GGTCCCACCA      
1680 
 
 
     TCACCACCAT CATCTCGTTC CTCGGGGCAG CAATCTCGCA TCCAATCGAC GCTTGCAGCA      
1740 
     GACACAGGCT CAAGTGGATG AGGTCGTCGA CATTATGCGA GTGAATGTTG ACAAGGTACT      
1800 
     CGAACGCGAT CAGAAGCTGA GTGAGCTGGA CGACAGGGCG GATGCCCTTC AAGCTGGGGC      
1860 
 
 
 
 
     CTCACAGTTC GAGACATCAG CCGCAAAACT GTAACCCGGG GTTTAAACCC GCTGATCAGC      
1920 
     CTCGACTGTG CCTTCTAGTT GCCAGCCATC TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT      
1980 
     GACCCTGGAA GGTGCCACTC CCACTGTCCT TTCCTAATAA AATGAGGAAA TTGCATCGCA      
2040 
     TTGTCTGAGT AGGTGTCATT CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGGA      
2100 
     GGATTGGGAA GACAATAGCA GGCATGCTGG GGATGCGGTG GGCTCTATGG CTTCTGAGGC      
2160 
     GGAAAGAACC AGCTGGGGCT CTAGGGGGTA TCCCCACGCG CCCTGTAGCG GCGCATTAAG      
2220 
     CGCGGCGGGT GTGGTGGTTA CGCGCAGCGT GACCGCTACA CTTGCCAGCG CCCTAGCGCC      
2280 
     CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT CGCCACGTTC GCCGGCTTTC CCCGTCAAGC      
2340 
     TCTAAATCGG GGGCTCCCTT TAGGGTTCCG ATTTAGTGCT TTACGGCACC TCGACCCCAA      
2400 
     AAAACTTGAT TAGGGTGATG GTTCACGTAG TGGGCCATCG CCCTGATAGA CGGTTTTTCG      
2460 
     CCCTTTGACG TTGGAGTCCA CGTTCTTTAA TAGTGGACTC TTGTTCCAAA CTGGAACAAC      
2520 
     ACTCAACCCT ATCTCGGTCT ATTCTTTTGA TTTATAAGGG ATTTTGCCGA TTTCGGCCTA      
2580 
     TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACGCG AATTAATTCT GTGGAATGTG      
2640 
     TGTCAGTTAG GGTGTGGAAA GTCCCCAGGC TCCCCAGCAG GCAGAAGTAT GCAAAGCATG      
2700 
     CATCTCAATT AGTCAGCAAC CAGGTGTGGA AAGTCCCCAG GCTCCCCAGC AGGCAGAAGT      
2760 
     ATGCAAAGCA TGCATCTCAA TTAGTCAGCA ACCATAGTCC CGCCCCTAAC TCCGCCCATC      
2820 
     CCGCCCCTAA CTCCGCCCAG TTCCGCCCAT TCTCCGCCCC ATGGCTGACT AATTTTTTTT      
2880 
     ATTTATGCAG AGGCCGAGGC CGCCTCTGCC TCTGAGCTAT TCCAGAAGTA GTGAGGAGGC      
2940 
     TTTTTTGGAG GCCTAGGCTT TTGCAAAAAG CTCCCGGGAG CTTGTATATC CATTTTCGGA      
3000 
     TCTGATCAAG AGACAGGATG AGGATCGTTT CGCATGATTG AACAAGATGG ATTGCACGCA      
3060 
     GGTTCTCCGG CCGCTTGGGT GGAGAGGCTA TTCGGCTATG ACTGGGCACA ACAGACAATC      
3120 
     GGCTGCTCTG ATGCCGCCGT GTTCCGGCTG TCAGCGCAGG GGCGCCCGGT TCTTTTTGTC      
3180 
     AAGACCGACC TGTCCGGTGC CCTGAATGAA CTGCAGGACG AGGCAGCGCG GCTATCGTGG      
3240 
     CTGGCCACGA CGGGCGTTCC TTGCGCAGCT GTGCTCGACG TTGTCACTGA AGCGGGAAGG      
3300 
     GACTGGCTGC TATTGGGCGA AGTGCCGGGG CAGGATCTCC TGTCATCTCA CCTTGCTCCT      
3360 
     GCCGAGAAAG TATCCATCAT GGCTGATGCA ATGCGGCGGC TGCATACGCT TGATCCGGCT      
3420 
#5 
#6 
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     ACCTGCCCAT TCGACCACCA AGCGAAACAT CGCATCGAGC GAGCACGTAC TCGGATGGAA      
3480 
     GCCGGTCTTG TCGATCAGGA TGATCTGGAC GAAGAGCATC AGGGGCTCGC GCCAGCCGAA      
3540 
     CTGTTCGCCA GGCTCAAGGC GCGCATGCCC GACGGCGAGG ATCTCGTCGT GACCCATGGC      
3600 
     GATGCCTGCT TGCCGAATAT CATGGTGGAA AATGGCCGCT TTTCTGGATT CATCGACTGT      
3660 
     GGCCGGCTGG GTGTGGCGGA CCGCTATCAG GACATAGCGT TGGCTACCCG TGATATTGCT      
3720 
     GAAGAGCTTG GCGGCGAATG GGCTGACCGC TTCCTCGTGC TTTACGGTAT CGCCGCTCCC      
3780 
     GATTCGCAGC GCATCGCCTT CTATCGCCTT CTTGACGAGT TCTTCTGAGC GGGACTCTGG      
3840 
     GGTTCGAAAT GACCGACCAA GCGACGCCCA ACCTGCCATC ACGAGATTTC GATTCCACCG      
3900 
     CCGCCTTCTA TGAAAGGTTG GGCTTCGGAA TCGTTTTCCG GGACGCCGGC TGGATGATCC      
3960 
     TCCAGCGCGG GGATCTCATG CTGGAGTTCT TCGCCCACCC CAACTTGTTT ATTGCAGCTT      
4020 
     ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC AAATAAAGCA TTTTTTTCAC      
4080 
     TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC TTATCATGTC TGTATACCGT      
4140 
     CGACCTCTAG CTAGAGCTTG GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT      
4200 
     ATCCGCTCAC AATTCCACAC AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG      
4260 
     CCTAATGAGT GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG      
4320 
     GAAACCTGTC GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC      
4380 
     GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC      
4440 
     GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA      
4500 
     ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG      
4560 
     CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT      
4620 
     CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA      
4680 
     GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC      
4740 
     TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT      
4800 
     AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG      
4860 
     CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG      
4920 
     CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT      
4980 
     TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGAACAGT ATTTGGTATC TGCGCTCTGC      
5040 
     TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG      
5100 
     CTGGTAGCGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG      
5160 
     AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG      
5220 
     GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT      
5280 
     GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TACCAATGCT      
5340 
     TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG TTCATCCATA GTTGCCTGAC      
5400 
     TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA      
5460 
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     TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC CAGCCAGCCG      
5520 
     GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAATT      
5580 
     GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTTGCCA      
5640 
     TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT      
5700 
     CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT      
5760 
     TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG      
5820 
     CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG      
5880 
     AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG      
5940 
     CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA      
6000 
     AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT      
6060 
     AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC GTTTCTGGGT      
6120 
     GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT      
6180 
     GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA      
6240 
     TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT      
6300 
     TTCCCCGAAA AGTGCCACCT GACGTC                                           
6326 
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